






Title of Document: CHARACTERIZATION OF LIVER X 
RECEPTORS IN PROSTATE CANCER 
CHOLESTEROL METABOLISM AND 
PULMONARY IMMUNE RESPONSE 
  
 Steven E. Trasino, Doctorate of Philosophy, 
2011 
  
Directed By: David Lei, Professor, Department of Nutrition 
and Food Science 
 
 Liver x receptors (LXRs) are central regulators cholesterol homeostasis 
and the innate immune response. As modulators of inflammation and cholesterol 
metabolism LXRs might diminish dyslipidemia and inflammation related 
pathologies caused by high fat (HF) diets or obesity. There is also data 
demonstrating that LXRs can protect against progression of prostate cancer (PCa), 
but little is known about the cholesterol modulating effects of LXRs in 
transformed cells.  The goal of this project is to characterize the cholester  
modulating properties of LXRs in two models of PCa and the anti-inflammatory 
properties of LXRs in swine bronchial alveolar macrophages (AMs). This project 
will also examine whether the anti-inflammatory and lipid lowering properties of 
the dietary probiotic bacteria Lactobacillus casei (L. casei), can interact with the 
LXR axis in AMs. Studies in two PCa cell lines, LNCaP and PC-3, revealed that 
LXR ligands regulate the LXR responsive genes, ABCA1 and ABCG1 through the 
LXRβ isoform and not LXRα in PC-3 cells, but only ABCG1 in LNCaP. LXR-
ABCA1 mediated reverse cholesterol transport (RCT) resulted in a decrease in 
plasma membrane lipid raft cholesterol domains in PC-3 cells, suggesting a 
potential anti-cancer axis for LXR activation. Studies in LNCaP and PC-3 cells 
also demonstrated that soy isoflavones can activate transcriptional activ tion of 
ABCA1 and ABCG1 in LNCaP and PC-3 cells through the LXRβ isoform, but did 
not lead to an increase in RCT. Metabolic and anti-inflammatory studies of LXR 
in AM from Ossabaw pigs fed either a control (C) diet, HF, HF plus L casei 
(HFPB) or L. casei alone (CPB) diet revealed that AM from HF fed pigs had 
significantly higher concentrations of cholesteryl-esters (CE) compared with AM 
from control (C) diet fed pigs.  Ex-vivo activation of LXR with the LXR ligand 
T0901317 opposed LPS mediated upregulation of IL-1β, IL-6, IL-8 and IL-10 
mRNA levels in AM from HF, HFPB and CPB fed pigs. Finally, it was observed 
that LPS stimulation lead to significant inhibition of LXR transcription of LXRα, 
ABCA1, ABCG1, cholesterol 25 hydroxylase (CH25H) and PPARγ in AM. This 
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Chapter 1: Literature Review of Liver X Receptors 
Discovery of Liver X Receptors     
 Nuclear receptor transcription factors (NRTFs) are intracellular receptors 
that bind to small lipophylic molecules, such as retinoids, fatty acids, vitamins 
(vitamin D) and steroid hormones (estrogen, glucocorticoids), and can regulate 
transcription of target genes by direct interaction with promoter region DNA 
sequences known as response elements (1,2). The response element for all 48 
members of the NRTF super family consists of a the DNA consensus sequence 
(AGGTCA) which is found as either a direct repeat (DR) or inverted repeat, 
separated by 3, 4 or 5 base pairs known as DR-3, -4 and -5 elements. Genes 
regulated by specific NRTF are identified and defined by the specific DR-X 
consensus sequence found in their transcription promoter region. For example, 
androgen receptor (AR) and vitamin D receptor-(VDR) binds to DR-3 elements in 
target genes, while thyroid hormone receptor (THR) and retinoic acid receptor 
(RAR) bind only to DR-4 and DR-5 promoter elements respectively (1,2).  
 NRTF are further subcategorized whether or not they reside in the cytosol 
(type I) or nucleus (type II). Type I NRTF translocate the nuclear as homo-dimers 
and bind to promoter region DR-3 elements known as hormone responsive 
elements (1,2) and are either recycled back to the cytosol or are marked for 
ubiquitination and rapid proteosomal degradation (1,2). Type II NRTF form 
obligate heterodimers with another type II NRTF member, retinoid x receptors 
(RXR), and reside in the promoter region of target genes in a transcriptionaly 
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repressed under the direction of numerous transcriptional co-repressor proteins 
(1,2). Upon ligand activation, types II NRTFs undergo conformational changes 
that promote the exchange of transcription co-repressors with co-activators 
allowing for transcriptional regulation of the target gene (1-3). The type II NRTF 
subfamily includes RAR, THR, VDR, peroxisome-proliferator-activated receptors 
(PPARs), and liver X receptors (LXR) (1-3). 
 Liver x receptors, NR1H3 (LXRα) and NR1H2 (LXRβ) are the newest 
members to be added to the type II family of NRTF.  In 1994 two laboratories 
separately discovered LXRα, and in 1995 four reported the discovery of LXRβ, 
initially coined ubiquitous receptor from screens of mouse liver and colon cDNA 
libraries (3-5).  In humans, the genes for LXRα and LXRβ are encoded on 
chromosomes 11 and 19 respectively (3). Molecular weight of the protein 
products are 45 kiloDaltons (kDa) for LXRα and 51 kDa for LXRβ (3). Both 
share approximately 78% protein sequence homology in their DNA and ligand 
binding domains (3-5). Expression patterns differ between each isoform, with 
LXRβ being expressed in all tissue, while LXRα is primarily expressed in liver, 
kidney, adrenals, adipose, small intestine and macrophages (3).  
 Among the members of the NRTF superfamily, LXRs show the highest 
sequence conservation across species with ~75% homology in the ligand binding 
domains between human and non-mammals (6, 7). Sequencing data of LXRs 
across mammalian and non-mammalian species demonstrates that mammals 
posses two LXR genes (LXRα and LXRβ) while non-mammalian species have 
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only express LXRβ, and invertebrates none (6). A single LXR gene duplication 
likely occurred before or in early mammalian evolution (6).  
 LXRs where initially coined orphan receptors until 1996 when oxygenated 
cholesterol metabolites, known oxysterols, where identified as endogenous 
ligands for LXRα and LXRβ (8). Oxysterols are generated from cholesterol either 
enzymatically by sterol hydroxylases or auto-oxidation (8). The majority of 
oxysterols are formed in the endoplasmic reticulum (ER) during cholesterol 
processing and are transported from the ER and golgi complex to the cytosol and 
nuclear compartments by a family of highly conserved proteins called oxysterol 
binding proteins (OSBP) and oxysterol related binding protein (OSBP-related 
proteins (ORPs) (9). Figure 1 shows some common structures of oxysterols 
synthesized from cholesterol (9).  
 
Figure 1. Oxysterols, with hydroxyl groups typically added to the sterol side-
chain carbons, are robust LXR ligands. Source: J Med Biol Res 2008; 41: 545-556. 
 Oxysterols are found very low concentrations in vivo, typically at 1:1000 
(~0.01µM vs. ~5000 µM) compared to cholesterol, but being more hydrophic than 
cholesterol, oxysterols can move more freely through cellular compartments 
increasing their potential as robust signaling lipids (9). Binding studies indicate 
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that oxysterols can activate LXRα and LXRβ at nanomolar concentrations and 
with similar efficiency (8, 9).  
 Like other members of the type II NRTF family, LXRs form obligate 
heterodimers with RXR and reside in the promoter region of target genes bound 
to a DR-4 consensus sequence, AGGTCAxxxxAGGTCA, known as a liver x 
receptor responsive element (LXRE) (3).  LXR: RXR heterodimers form pat of  
protein complex of transcriptional co-repressors proteins such as silencing 
mediator of retinoic acid and thyroid hormone receptor (SMRT) and nuclear 
receptor co-repressor (N-CoR) (10). These complexes maintain transcriptional 
repression of LXR responsive genes in the absence of ligand activation (10). 
Upon activation by oxysterols, LXRs undergo conformational changes that 
promote dissociation of SMRT and N-CoR, and association with co-activator 
proteins such as peroxisome-proliferator-activated receptor (PPAR) c co-a tivator 
1a (PGC-1a} PPARGC1), which facilitate the transcriptional activation of the 
target gene (8, 10) (Fig 2). Transcriptional regulation of basal LXRα m NA 
levels are self-regulated (a number of LXREs have been in the promoter of the 
LXRα gene) and protein levels of LXRα are dependant on phosphorylation of a 
number of key serine residues (11).  
 
Figure 2.  Model of LXR transcriptional regulation of gene expression.  
Source: J Clin Invest. 2006 Mar; 116(3):607-14. 
 5
 The initial discovery that LXRs are activated by cholesterol metabolites in 
vitro and not cholesterol itself, lead to speculation that LXRs may act as sensors 
of cellular cholesterol levels (12).  Studies of lipid metabolism in LXRα and 
LXRβ null mice confirmed that LXRs have a central role in the regulation of 
cholesterol metabolism in vivo. Studies by Mangelsdorf et al. and Gustafson et al. 
both demonstrated that LXRα -/- null mice fed a chow diet enriched with 2% 
cholesterol presented with gross hepatic and peripheral accumulation of 
cholesteryl-esters and elevated serum cholesterol levels (13, 14). LXRα -/- mice 
had diminished hepatic expression of genes central to cholesterol and lipid 
metabolism including cholesterol 7α-hydroxylase (CYP7A1), hydroxymethyl 
glutaryl (HMG)-CoA synthase/reductase, squalene synthase (SQS), sterol 
response element-binding protein 1 and 2 (SREBP1 and 2), sterol CoA desaturase 
(SCD)-1, and fatty acid synthase (FAS) (13,14). Gustafson et. al. also 
demonstrated that unlike LXRα -/- mice, LXRβ -/- null mice were not prone 
developing hepatic cholesterol lipidosis and serum dyslipidemia on a cholesterol 
enriched chow diet (14). The disparity between the lipid profile of LXRα -/- and 
LXRβ -/- mice is explained by the dominant role that LXRα has in hepatic 
regulation of the bile synthesis enzyme CYP7A1 (14).  LXRβ -/- null mice are 
able to cope with the lipid burden of a high fat diet because they retained LXRα 
regulation of CYP7A1 hepatic conversion of cholesterol to bile acids.  
LXR Regulation of Whole Body Cholesterols Levels  
 By the year 2000, an expanded role for LXR regulation of cholesterol 
metabolism outside of the liver was established when two studies demonstrated 
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that the transfection of RAW 264.7 cells and THP-1 macrophages with constructs 
that lead to overexpression of LXRα, resulted in a strong mRNA and protein 
upregulation of the cholesterol efflux transporters ATP-binding cassette, sub-
family A, member 1 (ABCA1) and sub-family member G 1 (ABCG1) and an 
increase in cholesterol efflux to lipid free apolipoprotein A-I (apo A-I). (15).  
Subsequent studies of cholesterol laden macrophages from low density 
lipoprotein (LDL) -/- null mice also demonstrated that natural and synthetic LXR 
ligands can increase mRNA and protein expression of ABCA1, ABCG1 
transporters and increase peripheral cholesterol efflux in vivo (16).   
 These studies, coupled with previous data from LXR -/- null mice, helped 
construct a distinct role for LXR in regulating whole body cholesterol levels. It is 
now understood that among the numerous effectors involved in the regulation of 
whole body cholesterol levels, LXRs exists as cellular cholesterol sensor  and 
function to limit absorption of dietary cholesterol, protect cells from the cytotoxic 
effects of cholesterol accumulation and permit for rapid catabolism and secretion 
of hepatic cholesterol and bile acids. In the intestine, post-prandial cholesterol 
absorption and reabsorption of hepatic cholesterol is regulated by LXR activation 
of cholesterol efflux pumps ABCG5 and ABCG8 (15). In peripheral tissue and 
cells such as smooth muscle or macrophages, excess cellular cholesterol derived 
from either plasma apolipoprotein B containing lipoproteins or de novo synthesis 
via the mevalonate pathway, is rapidly metabolized to oxysterols by a family or 
microsomal cytochrome P450 and mitochondrial hydroxylases such as CYP27A1, 
CYP46, cholesterol 25-hydroxylase (CH25H) (15). Binding of oxysterols to LXR 
 7
leads to increased mRNA transcription and protein translation of cholesterol 
transporters ABCA1, ABCG1, which use energy from ATP hydrolysis to 
transport plasma membrane free cholesterol to the outer plasma membrane leaflet 
where direct interactions with lipid poor apo A-I and immature HDL particles 
permit efflux and adsorption of free cholesterol (17).  The formation of immature 
HDL particles occurs only after ABCA1 cholesterol efflux to lipid poor apo A-1, 
which is followed by esterification of apo A-I bound cholesterol by the enzyme 
lecithin-cholesterol acyltransferase (LCAT) (17). Newly esterified cholesteryl-
esters partition to the interior of the apo A-I complex and results in the formati n 
of a more spherical, immature HDL particle (17,18). These particles remain in 
circulation and continue to remove excess cholesterol from other peripheral cells 
through interactions specifically with the plasma membrane cholesterol 
transporter ABCG1 (17).  Mature HDL particles can transport cholesteryl-esters 
to the liver in a process involving hepatic scavenger receptor B1 (SRB1), or 
through exchange of cholesterol for triglycerides from very low density and low 
density lipoproteins (VLDL and LDL), which deliver cholesterol to steroidogenic 
tissue or to the liver via LDL receptors (Fig 3). This process is collectively 
referred to as reverse cholesterol transport (RCT).  
 Studies of mice with tissue specific knockouts of ABCA1 have 
demonstrated that hepatic and intestinal expression of ABCA1 is a major 
determinant of circulating apo A-I protein and HDL levels (17, 18). This is due to 
a role for ABCA1 in transportation of newly synthesized apo A-I from the liver to 
peripheral circulation (17, 18). Inheritance of a loss of function mutation of the 
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ABCA1 gene results in a rare disorder known as Tangier’s disease characterized 
by peripheral cholesterol accumulation, severely depressed serum high density
lipoprotein, enlarged spleen and liver and risk for onset of atherosclerosis before 
the age of 20 (19).  
Figure 3. LXR mediates Reverse Cholesterol Transport.  
Source: Nature Reviews Cardiology. 6, 455-463, 2009 
  In the liver activation of LXRα directs hepatic β-oxidation of cholesterol 
to the bile acids, cholic acid (CA) and chenodeoxcholic acid (CDCA) by the bile 
acid synthesis enzyme cytochrome P450, member 3A4 (CYP3A4) (CYP7A1 in 
mice) (8). LXRα also directs the efflux of bile and free cholesterol via ABCG5/8 
from the liver, through the hepatic bile duct, to the duodenum where bile salts 
facilitate the absorption of post-prandial lipids and lipid soluble vitamins (e.g. 
vitamin A, D, K and triacylglycerol) (8).  The majority of cholesterol and bile 
salts secreted into the small intestine are reabsorbed with little loss of cholesterol 
in the feces (13). 
 The gene duplication and evolution of both LXR isoforms as functionally 
redundant paralogs within the higher vertebrate and mammal kingdom occurred in 
parallel to appearance of the of the hepatobiliary tract and enterohepatic 
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circulation (6, 7). LXRs harmonize these pathways with two vital components of 
mammalian lipid metabolism: 1) preventing cholesterol accumulation and toxicity 
in peripheral tissue and 2) the need for hepatic cholesterol catabolism, synthesi  
of bile acids for assimilation of dietary lipids and lipid soluble vitamins. 
Undoubtedly, the evolution of LXRs and other hormone NRTF that are activated 
by cholesterol derivatives occurred in response to the increasing presence of 
dietary cholesterol from marine or terrestrial food sources as higher mammals 
evolved.  
 Studies have also demonstrated an emerging role for hepatic LXRα as a 
nutrient sensor in the regulation of carbohydrate metabolism and energy 
homeostasis (20). During post-prandial carbohydrate metabolism, D-glucose and 
glucose-6-phosphate can act as direct LXR ligands with affinity equal to 
oxysterols and increase expression of hepatic lipogenic enzymes such as sterol 
regulatory element binding protein isoform 1-c (SREBP1-c), and fatty acid 
synthase (FAS), as well genes involved in decreasing glucose output and 
increasing glucose utilization, including glucokinase, phosphoenolpyruvate 
carboxykinase and glucose 6-phosphatase (20). 
LXRs are Anti-inflammatory and Cardio-Protective   
 Interest in the immuno-modulating properties of LXR grew after a number 
of studies demonstrated that epidermal application of LXR ligands, 22(R)-
hydroxycholesterol and 24(S), 25-epoxycholesterol in a model of contact 
dermatitis lead to inhibition of keratinocyte proliferation, differentiation and 
normalization of epidermal barrier function (21). Consistent with this, another 
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study found that oxysterol administration to pregnant mice increased the 
development rate of the fetal epidermal permeability barrier (22).  Both LXRα 
and LXRβ are expressed in epidermis, but it was demonstrated that epidermal 
LXRβ is responsible for the anti-inflammatory and anti-proliferative effect of 
LXR ligands on keratinocytes in vivo (21).  
 A more expansive role for LXR in modulating inflammation was 
demonstrated in 2002, when Totontoz et. al. reported that administration of the 
synthetic LXR ligands, GW3965 or T0901317 (T09) to apo E -/- or LDLR -/- null 
mice significantly diminished atherosclerotic plaques and atheroma formti n 
(23). He went on to publish a report demonstrating that synthetic and natural LXR 
ligands administered to apo E -/- or LDLR -/- null atherosclerotic mice caused 
robust antagonism of lipopolysaccharide (LPS) mediated mRNA expression and 
secretion of pro-inflammatory mediators such as iNOS, TNFα, IL-6, IL-1β, MCP-
1 in peritoneal macrophages (24). Atherosclerotic plaques in T09 treated mice 
were significantly diminished and profiling of aortic lesions revealed a decreased 
expression of matrix metallopeptidase 9 (MMP-9), an enzyme involved in the 
breakdown of extracellular matrix in normal tissue and implicated in the etiology 
of atheroma lesion formation (24). Numerous studies have since demonstrated a 
cardio-protective effect of LXR ligands in cell and animals models of obesity and 
cardiovascular disease (25-27). A central molecular paradigm shared by these 
studies is that LXR activation is cardio-protective because of its ability to: i) 
prevent macrophages foam cell formation by increasing cholesterol efflux via 
ABCA1 and ABCG1 and ii) antagonize expression of pro-inflammatory 
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mediators such as MCP-1, TNF-α and IL-1β, that are positively associated with 
atheroma formation (18).   
 LXR ligands can oppose LPS/toll like receptor -4 (TLR4) mediated 
inflammation in macrophages isolated from LXRα -/- and LXRβ -/- null mice, but 
not from LXRα/β -/- double knockout mice demonstrating that both LXR 
isoforms posses anti-inflammatory properties (24)  The anti-inflammatory effect 
of LXR activation is not exclusive to macrophages or the dermis, but occurs 
systemically as it has been demonstrated that mice challenged with i.p. LPS and 
treated with LXR ligands have broad antagonism of inflammation in the liver, 
kidney, small intestine, lungs and smooth muscle (28). Inflammatory mediators 
opposed by LXR, such as TNF-α, IL-6, and IL-1β, do not posses LXREs in their 
DNA promoter regions; therefore an indirect mode of LXR opposition of these 
targets has been proposed. One model demonstrates that LXRs oppose pro-
inflammatory mediators by nuclear trans-repression of the transcription factor
NF-kB (24).  
 LXR ligands only suppress inflammation in LPS or toll like receptor 3 or 
4 (TLR3/4) stimulated macrophages, not in naive, unstimulated cells (24).  
Furthermore, LXR antagonism of TLR3/4 signaling also protects macrophages 
from LPS mediated suppression of cholesterol efflux, as it has been demonstrated 
that LPS can inhibit ABCA1, ABCG1 mRNA expression and lead to pathological 
cholesterol retention and apoptosis in macrophages in an LXR dependant manner 
(24). The uncoupling of the anti-inflammatory properties of LXR in the absence 
of an immune response likely occurs because of the high risk that phagoctytic 
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cells such as macrophages have for accumulating pathological concentration of 
cholesterol during phagocytosis of cellular debris. Cross talk between TLR3/4 and 
LXR mediated cholesterol efflux may provide new insight into mechanisms 
through which pathogens evade immune detection and contribute to inflammatory 
and metabolic related disease such as atherosclerosis.  
 LXRs are a vital molecular target in treatment of cardiovascular disease 
because the potential for LXR ligands to increase cholesterol metabolism and 
oppose the inflammatory response. However, one drawback in developing LXRs 
as a cardio protective target is the increased serum triglycerides which accompany 
hepatic LXRα activation of lipogenic genes FAS and SREBP-1c (12, 20). The 
information gap regarding LXR as a nutrient sensor is still closing, but the 
observed triglyceridemia accompanying LXR activation is counterintuitive and 
probably underscores how little is understood about LXR biology. Development 
of synthetic ligands specific for LXRβ would allow for selective LXR activation 
of only peripheral RCT and minimize hepatic expression of lipogenic genes. 
Studies have already identified specific LXRβ ligands which result in cardio-
protection in vivo without affecting LXRα hepatic lipogenic genes (26).  
LXR Regulation of the Innate Immune Response   
 Because LXR activation negatively regulates TLR4 mediated 
inflammatory response, it has been suggested that LXR activation may 
compromise host immunity. This question was examined in two studies on the 
effects of LXR of pulmonary immunity. Birrell et. al. demonstrated a that 
administration of the LXR ligands T09 or GW3965 to male Wistar rats was 
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associated with decreased pulmonary neutrophilia in response to LPS challenge 
(29). Neutrophils from LXR treated rodents showed decreased chemotaxis in 
response to the chemokine interleukin 8 (IL-8). Expanding on these results, a 
study by Smoak et. al. again demonstrated that administration of T09 to mice for 
5 days lead to robust antagonism of LPS or Escherichia coli mediated pulmonary 
inflammation, but left LXR ligand treated mice with significantly decreased 
pulmonary neutrophilia and a significantly increased susceptibility to infecton by 
Klebsiella pneumoniae compared to vehicle treated control mice 24 and 48 h post 
infection (30).  Moreover, T09 treated mice showed increased mortality post-
infection compared to vehicle treated controls. However, these studies did not 
demonstrate whether the negative effect of LXR activation on pulmonary 
immunity is related to inflammation or whether these observations where a 
secondary effect of LXR mediated cholesterol modulation. Closer examination of 
the impact of LXR mediated cholesterol metabolism on pulmonary immunity may 
be warranted in light of studies demonstrating that loss of lung expression of 
ABCA1 or ABCG1 negatively alters pulmonary function, alveolar macrophage 
immune response and potentially impairing pulmonary host immunity (31, 32).  
 Nevertheless, it is still unclear what role (negative or positive) LXR
activation has on innate immunity. Further complicating the issue is data 
demonstrating that loss of basal LXR gene expression negatively impacts the 
innate immune response.  Valledor et. al demonstrated that LXR stimulated bone-
marrow-derived macrophages (BMDM) isolated from LXRα/β -/- null mice are at 
increased risk for apoptosis from infection by Bacillus anthracis, Escherichia 
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coli, and Salmonella typhimurium (33).  BMDM from LXRα/β -/- null mice had 
altered expression of genes directly involved in modulating macrophage survival 
including pro-apoptotic effectors caspases 1, 4, 7 and 12 and Dnase 113, and anti-
apoptotic genes AIM/CT2, Bcl-XL, and Birc1a (33). Loss of LXRα or LXRβ 
expression in mice also increases the total burden of infection by intracellular 
Listeria Monocytogenes (LM)  and Mycobacterium tuberculosis (TB) compared to 
WT mice and impairs macrophages clearance and phagocytosis of LM (33). 
Moreover, peritoneal macrophages (PM) isolated from LXRα/β null mice are less 
resistant to anti-apoptotic factors secreted by LM due to loss of expression of the 
anti-apoptotic gene SPα (34). SPα is a LXR regulated gene in macrophages and 
prevents macrophages apoptosis during LM infection (34).  An expansive model 
of the cross-talk between TLR3/TLR4 and LXR in regulating cholesterol 




Figure 4. A model for cross talk between cholesterol metabolism and the innate 
immune response. Source: Clin Invest. 2006 Mar; 116(3):607-14. 
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Liver X Receptors and Disruption of Lipid Raft Signaling   
 LXR-ABCA1 mediated efflux of free cholesterol from macrophages has 
been vigorously studied, but broad knowledge of the mechanics involved in the 
active transport of free cholesterol across the plasma membrane to circulating 
lipoprotein particles is still growing. However there is consensus that during early 
steps of cholesterol efflux, ABCA1 facilitates the “flipping” of cholesterol and 
other phospholipids from the inner to the outer membrane leaflet in a process 
involving microdomains known as lipid rafts (35). Lipid rafts domains are 
cholesterol rich, plasma membrane microdomains that contain a comparatively 
higher concentration of neutral lipids (up to 50% higher) such as cholesterol and 
saturated phospholipids, glycosphingolipids and sphingomyelin (36). In 
macrophages and other metabolically active cells, there are a number of 
intracellular and plasma membrane kinetic pools of cholesterol which are 
segregated for efflux by ABCA1, and some data suggests that the largestand most 
active pool of membrane cholesterol is derived from lipid rafts domains (37). 
 Lipid rafts were first identified in electron micrographs as nanoscale 
invaginations in the plasma membrane (Fig 5A). Cholesterol and the saturated 
acyl chains of the phospholipids with these domains form strong hydrogen bonds 
and permit formation of condensed protein lipid microdomains that appear as 
“rafts” floating within the more loosely packed lipid bi-layer (38, 39). Rafts nd 
raft proteins have been characterized by their propensity to resist extraction from 
membrane using conventional detergents such as triton-X 100, coining the term 
detergent resistant membrane fractions (DRMs) (38). Visualization of lipid raft in 
 16
living cells has been aided by fluorescent labeling of raft associated protein 
ganglioside m1 (Fig 5B) and fluorescence resonance energy transfer (FRET). 
From these techniques, rafts have been visualized as 50-70 nm structures which 
continually come together and dissociate with other raft domains as transitory 
membrane structures (38, 39). The presence of cholesterol’s rigid ring structure 
within these domains increases “liquid order” and is a vital part of maintaini g 
raft integrity, as disruption of membrane cholesterol diminishes the continuity of 
raft: raft membrane interactions (38-40).   
 Functionally, raft domains permit rapid, lateral co-localization of receptors 
with other co-receptors, kinases and other signaling machinery in complex 
referred to as a raft signalosome (40). Signalosomes form larger, more stable 
signaling platforms which facilitate the amplification of signal transduction from 
scattered membrane receptors (38-40). An example of a raft associated receptor is 
T cell antigen receptor (TCR), which, along with its co-activator CD-3, rapidly 
move into lipid raft domains upon binding of a major histocompatibility complex 
(MHC) from an antigen presenting cell (APC), where SRC protein tyrosine 
kinases (LCK and FYN) phosphorylate the TCR-associated CD3 complex and 
amplify signal transduction and T cell mediated adaptive immunity (41) (Fig 5C). 
Other examples of membrane receptors associated with raft domains include 
Immunoglobulin E (IgE) signaling, chemokine receptor CXC-4, (CXCR4), C-C 
chemokine receptor type 5 (CCR5), epidermal growth factor receptor (EGFR) and 
interleukin-6 receptor (IL-6R) (42). The signal transduction and protein 
trafficking occurring in cholesterol rich raft domains are not only relevant to 
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normal cellular physiology, but have been shown to be constitutively active in a 
number of transformed cells (36, 43-45).   
 
 
Figure 5. Lipid Rafts: A) Lipid rafts viewed under an electron microscope. B) 
Fluorescent micrograph of lipid raft domains. C) T-Cell receptor (TCR) activation 
model. Upon ligand activation, individual TCRs mobilize into larger signaling 
assemblies within lipid raft domains. Sources A, B: Molecular Biology of the Cell. 
4th edition. Alberts B, Johnson A, Lewis J, et al.New York: Garland Science; 2002. C: 
Nature Reviews Molecular Cell Biology. 2010;11, 688-99. 
 
 Studies have demonstrated that LXR-ABCA1 mediated efflux lowers raft 
cholesterol, alters membrane dynamics and interactions of raft domains leadi g 
suppression of raft dependant receptor assembly and signal transduction (45-49).   
A profound example of this has been demonstrated in studies of human immuno-
deficiency virus 1 (HIV-1). HIV-1 infection of T cells involves a receptor 
complex formed by CD4 and a lipid raft associated chemokine receptors CCR5 or 
CXCR4 (45-47). It was recently demonstrated that the synthetic LXR ligand T09 
impairs CCR4/CXCR4 raft domain assembly with CD4 and HIV-1 entry into T-
cells through its upregulation of LXR-ABCA1 mediated cholesterol efflux (48).  
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LXR-ABCA1 mediated cholesterol efflux has also been shown to prevent lateral
assembly of TLR4 into raft domains and signal transduction to the pro-
inflammatory MyD88 pathway (49). Numerous studies have demonstrated that 
administration of cholesterol binding agents can oppose a number of disease 
specific raft signaling cascades (45-49). However the discovery of that LXR-
ABCA1 may serve as an endogenous negative regulator of raft signaling 
introduces the potential to exploit an endogenous pathway to oppose raft signal 
transduction that is relevant to disease or other pathological conditions.  
 There are two models which are thought to most closely predict the 
sequential order how ABCA1 disrupts cholesterol from lipid raft domains. One 
model asserts (Fig 6A), that ABCA1 exists on a transition region of raft domains 
and through its ATPase function, generates cholesterol rich export domains by 
lateral translocation of cholesterol from lipid raft domains to adjacent non-raft 
domains (35). A second model, (Fig 6B), proposes that ABCA1 effluxes free 
cholesterol (FC) and phospholipids (PL) in two steps. ABCA1 first interacts with 
circulating apo A-I particles which undergo conformational changes permitting 
removal free cholesterol from adjacent lipid raft domains (35).  
 
Figure 6. Two models for ABCA1 disruption of Lipid Raft Domain Cholesterol. 
Source: J.Clin Invest. 2002; 7:899-904. 
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 As modulators of lipid raft cholesterol levels, LXRs and ABCA1 represent 
a vital tool in the examination of raft: raft transient interactions and mobilization 
of membrane receptors into these domains during signal transduction. 
Capitalizing on the raft disrupting effects of cholesterol efflux may also reveal 
that the partitioning of membrane cholesterol is equally important as absolute 
cholesterol levels are in the pathogenesis of disease. This would make LXRs and 
ABCA1 an attractive clinical target for a number of diseases as our current 
understanding of the specific role that membrane lipid microdomains have in the 
etiology of disease increases.  
Prostate Cancer, Cholesterol and Liver X Receptors 
 In recent years a number of large epidemiological studies have 
demonstrated an association between serum cholesterol levels and risk for 
advanced PCa (50-54). Prostate tumors, compared to other tumor types, appear to 
be specifically sensitive to growth inhibitory effect of either dietary or 
pharmacological cholesterol lowering (50, 53). Cholesterol levels are 
comparatively higher in normal prostatic tissue than other organs, which may 
partly explain why prostatic tumors are prone to accumulate cholesterol and why 
growth of PCa tumors are highly sensitive to cholesterol lowering agents (60,54). 
The accumulation of cholesterol in prostate and other cancers might reflect 
metabolic changes in transformed cells which support unchecked cell growth. The 
current appreciation of cholesterol as promoter of advanced PCa growth provides 
researchers the rationale to study the cholesterol metabolic pathways in 
transformed cells as novel targets for therapy. Statin therapy is associated w th a 
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decreased risk for advanced PCa and experimental evidence suggests that this 
effect is associated with its cholesterol lowering properties (54). As a vital part of 
the cellular axis for regulation of cellular cholesterol levels LXRs also have been 
demonstrated to possess anti-cancer properties in models of PCa (54- 56). Studies 
have demonstrated that oxysterols and the synthetic LXR ligand T0901317 can 
inhibit growth of prostate carcinoma cells in culture and repress progression of 
androgen dependent tumor xenografts to a more aggressive androgen independent 
phenotype (54-56). The ability of LXR to inhibit PCa tumors to adopt a refractive, 
hormone independent phenotype experimentally is in line with population data 
demonstrating a specific relationship with cholesterol and advanced PCa and a 
cholesterol steroid axis in advanced castration resistance PCa (54- 56). A recent 
demonstrated that LXR ligands can reduce AKT mediated signal transduction in 
cholesterol rich membrane raft domains in LNCaP cells in vivo (57).  There is 
growing evidence that LXR ligands can modulate growth and cancer related 
signalling in cancer others than prostate (58-59), however little if any information 
on the effects of LXRs on cholesterol metabolism in transformed cell lines has 
been extensively studied. Further characterization of LXR biology in transformed 
cell lines will contribute the current knowledge gap on this topic, and more 
importantly, understanding the cholesterol regulatory axis by LXR in transformed 
cells is vital given the current belief that serum and intra-tumor cholesterol levels 
positively affect tumor growth (50, 59).  
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Anti-Prostate Cancer and Lipid Lowering Properties of Soy 
 A number of population studies in East Asian males have found a 
correlation between consumption of soy derived foods and a reduced risk for 
developing prostate cancer (PCa) and other maladies (61-65).  Isoflavones are a 
class of compounds found at high concentrations in soy derived foods, and are 
believed to be responsible for their anti-PCa properties (61-65). In some cohorts 
isoflavones can be detected a micromolar concentration in plasma, urine and 
prostatic fluid of Asian males consuming a soy rich diet (61-65). The most 
commonly found isoflavones found in soya are genistein, daidzein and glycitein 
(61-65). Equol, a metabolite of daidzein also found in biological specimens of 
individuals with high soy consumption (63). Genistein, as the most abundant 
isoflavone in soy, has been shown to be a robust inhibitor of protein tyrosine 
kinase activity, which may inhibit cancer cell proliferation and increase apoptosis 
(66).  Animal and in vitro studies have identified a number of anti-PCa properties 
of isoflavones including, tyrosine kinase inhibition, modulators of angiogenesis 
and apoptosis (66, 67). Work in this laboratory has demonstrated that some 
isoflavones can specifically inhibit androgen receptor (AR) mediator signalin  in 
hormone responsive LNCaP cells (66). Androgenic hormones such as 
dihydrotestosterone (DHT) signal their AR and are positively associated with 
PCA risk and progression (67). Isoflavones can retard the growth of PCa tumors 
experimentally, however doses experimentally administered animals could be 10 
times higher than the equivalent for human consumption (61-65). Epidemiological 
evidence is inconsistent as to whether these properties of soy or isoflavones result 
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in PCa prevention in individuals with high soy consumption or to healthy men 
without evidence of clinical PCa (65).   
In addition to the anti-PCa properties of soy isoflavones, these compounds 
have also been reported to posses anti-atherogenic and cholesterol lowering 
abilities (68-71). Animal and human studies have demonstrated that consumption 
of soy and soy isoflavones can reduce risk factors for cardiovascular disease 
including lowering low density lipoprotein (LDL) cholesterol levels, increasing 
high density lipoprotein (HDL) cholesterol and increase HDL/LDL cholesterol 
ratios (68-71).  As with isoflavones and PCa, the relationship between isoflavones 
and cholesterol modulation are controversial (68-71). Nevertheless, the 
cholesterol lowering properties of soy isoflavones may provide a new paradigm to 
analyze their anti-PCa properties as new data suggests that cholesterol is also 
involved in prostate carcinogenesis (68-71).  
Pulmonary Immunity, Cholesterol and Liver X Receptors 
 LXR is also a major pillar in the regulation of the innate immune response 
of pulmonary alveolar macrophages (AMs).  In the lungs, LXR is expressed not 
only by AMs, but a number of other immune cell types including, dendritic cells, 
neutrophils, and type 2 alveolar cells (72). AMs are found in the alveolar spaces 
of the lungs and function to destroy invading bacteria or other elicitors of the 
innate immunity (72). The binding of bacteria, debris or immunogenic elicitors 
trigger AMs to engulf bacteria or foreign particles and destroyed them with the 
aid of peroxides and other reactive oxygen specifies (72).  Activation also causes 
AMs to secrete pro-inflammatory cytokines and chemokines such as IL-1β, TNF-
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α, IL-6 and MCP-1 which stimulate the infiltration of other inflammatory cells 
such as monocytes, eosinophils, neutrophils, B cells, and T cells into the lungs 
where they orchestrate a collective immune response (72). AMs aid in resolution 
of the pulmonary inflammatory response by clearing cellular debris, apoptotic 
immune cells and secreting anti-inflammatory mediators (72).  Under 
circumstances of acute pulmonary infection, the inflammatory response subside 
once the stimulus is removed (72). However, there are circumstances where 
pulmonary and systemic inflammation is chronic. Some causes are persistence of 
immuno resistance pathogens, continued inhalation of foreign particles, 
autoimmune disorders such as pulmonary fibrosis and morbid obesity (73, 74). 
The danger in unresolved chronic pulmonary or systemic inflammation is the 
onset of continuous tissue destruction and repair cycles which further damage 
tissue and may contribute to altered pulmonary and systemic immunity and 
metabolic disorders such as insulin resistance and type 2 diabetes (73). LXRs 
oppose TLR4/NF-kappaB mediated release of immunogenic factors from both 
peritoneal and AMs, such as IL-1β and TNF-α (24). These inflammatory 
mediators are essential to resolution of infection as they function to propel the 
acute phase inflammation forward. However, in light of the current paradigm that 
unchecked, chronic inflammation is associated with a number of metabolic 
diseases, the anti-inflammatory properties of LXRs propel them to the centerof a 
debate. This relates to the role, if any, that LXRs have in stunting the 
inflammatory response to diminish chromic inflammation, but not to the degree 
which can compromise host pulmonary immunity. The data is clear that the net 
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effect of the short term by LXR activation during pulmonary infection is anti-
inflammatory, but may compromise host immunity in the short term (72-73).  
Therefore, the beneficial effects of LXR activation on the innate inflammtory 
response may depend on whether it is in the context of the chronic inflammation 
or acute host infection. Examining the balance between these two extremes is 
vital to understanding how LXRs may fit into therapeutic approaches to mitigate 
inflammatory related conditions.  
 A second component of pulmonary immunity is the role of LXR in 
regulating cholesterol metabolism (72-74).  An important development in our 
understanding of the etiology of atherosclerosis is that as a molecule, cholster l 
is proinflammatory (76). The basis of this view comes from studies demonstrating 
that monocytes recruited and activated at endothelial cell injury engulf modi ied 
cholesterol molecules via their scavenger receptors CD36 and SCARB1 which 
elicits an acute inflammatory response in macrophages marked by increased 
secretion of inflammatory cytokines TNF-α, IL-1β and IL-6 (76, 18). Loss of 
CD36 auto regulation leads to continued cholesterol phagocytosis and foam cell 
formation (18). Experimentally, impaired LXR mediated cholesterol efflux leads 
to foamy macrophages which are associated with hyper secretion of inflammatory 
mediators and impaired phagoctytic function (77). There is now evidence that 
hypercholesterolemia can have a similar effect in AMs (72-75).  As in peripheral 
macrophages, activation of LXR in AMs results in increased expression of 
ABCA1, ABCG1 and cholesterol efflux (72-75). However loss of cholesterol 
efflux capacity in mice genetically deficient in either ABCA1 or ABCG1 leads to 
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abnormal pulmonary function and formation of large populations of lipid-laden 
AMs (72-77). Moreover mice lacking ABCG1 expression have chronic 
pulmonary inflammation marked by increased mRNA expression of TNF-α, Mip-
1, IL-1β (72-77). Similarly, LXRα null mice show pulmonary lipidosis, 
inflammation and increased risk for pulmonary infection (72-77).  
 Collectively these studies suggest that the changes which peritoneal 
macrophages (PM) undergo as results of hypercholesterolemia and foam cell 
formation may also occur in AMs exposed to high serum cholesterol levels. As in 
PM foam cells, AM foam cells may exhibit an altered immune response 
characterized by a hypersensitivity to LPS. The risk of a heightened inflammatory 
response is that seen under condition of chronic inflammation where heightened 
tissue destruction-repair cycles ultimately impair pulmonary functio  and increase 
host susceptibility to additional infection or pulmonary insult. Therefore it should 
be examined whether dietary hypercholesterolemia can lead to foamy AMs and 
subsequent changes in response to LPS. Furthermore, LXR activation in these 
cells should be tested for any anti-inflammatory capacity. Such studies would be 
the first characterization of dietary affects on pulmonary function and may 
provide the basis to develop LXR ligands as anti-inflammatory agents in persons 
with chronic pulmonary inflammation.   
Significance of the Current Project to Human Health 
Chapter 2: Studies of Liver X Receptors and Prostate Cancer 
 The current body of data demonstrating an association between cholesterol 
and advanced PCa warrants the examination of cholesterol modulating therapies 
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that could decrease the risk for advanced PCa.  Population studies have already 
demonstrated that long term use of the class of cholesterol lowering agents known 
as Statins (HMG-CoA reductase inhibitors) among men is associated with a
decreased risk for advanced PCa and experimental studies suggest that the 
cholesterol lowering effect of statins specifically targets lipid raft domain 
cholesterol and associated membrane signaling (61, 62, 68).  Lipid raft signaling 
represents a potential target in cancer and other pathologies such as HIV-1, where 
membrane raft signaling and integrity is linked to membrane cholesterol levels
and propagation of disease specific signaling (44, 45).  
 In light of data demonstrating that LXR ligands can oppose PCa 
progression and disrupt lipid raft domains in macrophages and T-cells, chapter 2 
of this project will specifically examine whether LXR ligands can modulate 
cholesterol metabolism in PCa cells and lead to alterations in lipid raft domain 
cholesterol levels. I hypothesize that LXR activation in transformed PCa 
epithelial cells will results in robust regulation of genes central to LXRmediated 
cholesterol efflux, ABCA1 and ABCG1, and that LXR-ABCA1 mediated 
cholesterol efflux will alter intra-cellular cholesterol levels and modulate lipid raft 
domains.  
 Data from this project could provide novel understanding of whether LXR 
ligands could be developed as cholesterol and lipid raft modulating agents in 
studies of PCa. This data would contribute to the growing body of data examining 
the role that cholesterol has in progression of prostate and other solid tumors.  
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Chapter 3: Studies of Isoflavones as LXR Modulating Agents 
 Studies of soy and soy isoflavones have been examined for more than a 
decade for their cholesterol lowering and anti-PCa properties (76). However th r  
is a paucity of data examining whether the cholesterol lowering properties of 
isoflavones involves interactions with the LXR axis and whether this can occur in 
PCa cells. This is a vital question because of the current appreciation for the role 
of cholesterol in promoting PCa and for the evidence suggesting that isoflavones 
possess anti-PCa properties in humans (61, 72). Data from this project could 
provide the basis to further study isoflavones for their LXR modulating properties 
and for identifying dietary compounds which may interact with a particular LXR 
isoform. There is some evidence that soy isoflavones can increase expression of 
LXR responsive genes in liver (82), therefore I hypothesize that some isoflavones, 
which have been shown to possess anti-PCa properties, will increase expression 
of LXR responsive genes in PCa cells. If so, I hypothesize that isoflavones will be 
able to increase LXR-mediated cholesterol efflux in PCa cells.  
 Chapter 3 will specifically examine whether soy derived isoflavones can 
modulate gene expression of LXR responsive genes ABCA1 and ABCG1 and 
LXR mediated cholesterol efflux in PCa cells. Data from this project could 
provide important understanding of how dietary isoflavones might discharge their 
anti-cancer effect in light of the positive relationship between cholesterol and 
advanced PCa (61). Moreover, this project will seek to determine which LXR 
isoform may be involved in regulation of LXR responsive genes. This is 
 28
important as a number of studies have attempted to identify ligands which can 
specifically modulate ABCA1 and ABCG1 through the LXRβ isoform (83).  
Chapter 4: Studies Examining the Effects of a HF Diet and Probiotics on the 
LXR Axis and Inflammation in Alveolar Macrophages 
 HF diets can alter pulmonary cholesterol levels and pulmonary function, 
but it is unclear if they can modulate pulmonary inflammatory response mediated 
by AM (84-86). Experimental evidence also demonstrates that AM that lack the 
capacity to efflux excess cholesterol via LXR accumulate excess cholester l rich 
lipid droplets and take on a foam cell macrophage phenotype (31,32). Foam cell 
AM exhibit an exaggerated immune response and may provide a link between 
hypercholesterolemia and altered pulmonary inflammatory response (31, 32). It is 
unclear, however, if wild type animals on a HF diet also have evidence of AM 
foam cell formation and whether this associated with an altered immune response.  
  Therapies aimed at modulating inflammation and cholesterol metabolism 
in the lungs might ameliorate or diminish inflammatory and lipid related 
pathologies of the lung (30-32).  Moreover, identifying novel therapeutic targets 
of lipid metabolism and inflammation may also be beneficial in cases of obesity 
related pulmonary lipidosis that is to poor lung compliance and increased risk for 
respiratory infection in some adults (88, 89). LXRs are ideal therapeutic targets 
for studying lipid and inflammatory related conditions due to their cholesterol 
lowering and anti-inflammatory properties (24).  Another therapy actively studied 
for potential anti-inflammatory and lipid lowering properties in humans is 
consumption of probiotic rich foods (90-93). Probiotics are lactic acid producing 
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bacteria that have been demonstrated to result in a broad anti-inflammatory effect 
of gut mucosal mediated immunity (90-93). There is also evidence that probiotic 
can have systemic anti-inflammatory effects (90-93). There is little information 
however on whether probiotics can benefit pulmonary immunity and lipid 
metabolism. As with LXRs, some probiotics strains posses anti-inflammatory and 
lipid lowering properties (90-93) therefore also represent a valuable therapeutic 
target for adults with pathologies involving chronic inflammation such as asthma 
or dyslipidemia related to obesity, lifestyle or genetic factors.  
 Chapter 4 will examine whether a HF diet can lead to AM foam cells 
formation and affect the inflammatory response in AM. This chapter will also 
examine whether LXR activation can diminished the inflammatory response in 
stimulated AM. Moreover, this project will also examine whether the probiotic 
bacteria L. casei is associated with any anti-inflammatory or lipid lowering effects 
in AM. Lastly, this project will also examine whether the endotoxin LPS, can 
oppose LXR transcription in AM. This has been demonstrated to be a mechanism 
through which pathogens can alter macrophage cholesterol metabolism leading to 
a diminished immune response. There has been no examination of whether 
probiotics can modulate the LPS antagonism of LXR in AM.  
 I hypothesize that HF feeding will lead to evidence of foam cells 
formation in AM marked by CE accumulation in AM.  I also hypothesize that 
LXR activation will result in a broad anti-inflammatory effect in stimulated AM. 
Lastly, I hypothesize that, as it has been shown in macrophages, that LPS will 
antagonize LXR transcriptional axis in AM.  
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 Data from this project can provide a better understanding of the role that 
obesogenic diets, hypercholesterolemia and LXRs have on pulmonary lipid 
metabolism and immunity. Moreover, data from this project will increase 
understanding of the potential benefits of dietary probiotics on host immunity and 
lipid metabolism and possibly justify further examination of LXRs and probiotic 














Chapter 2: Characterization of Liver X Receptors in Prostate 
Cancer Epithelial Cells 
INTRODUCTION 
Experimental Rationale for LXR Studies in Prostate Cancer Cells 
 According to the American Cancer Society, advanced and metastatic 
prostate cancer (PCa) remain the most prominent cancer type and the second 
leading cause of all cancer deaths among males in the United States (94). 
Although there are no established risk factors for PCa, epidemiological and 
experimental studies have demonstrated a specific association between elevated 
cholesterol levels and high grade and advanced PCa (61-64).  A number of large 
epidemiological studies demonstrated that men who maintain healthy cholester l 
profiles, either through diet or pharmacological use of cholesterol lowering agent 
3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase inhibitors (statins), 
have lower risk for developing advanced PCa (62-64). The mechanisms 
surrounding the association between serum cholesterol and PCa are not well 
understood, but there is evidence for more than 70 years that prostate and other 
solid tumors accumulate higher levels of neutral lipids such as cholesterol and 
triglycerides compared prostatic tissue from normal men and men with benign 
prostatic hyperplasia (61).  
 Recent evidence demonstrated that cholesterol accumulation in PCa 
tumors increases the content of plasma membrane cholesterol rich domains 
known as lipid rafts (94, 95). Rafts are cholesterol rich lipid platforms in the 
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plasma membrane involved in amplification of extracellular signal transduction of 
numerous biological pathways (36). Accumulation of cholesterol in PCa tumors 
may be involved in a number of metabolic pathways required for unchecked 
growth during cancer progression and recent evidence demonstrates that statins 
specifically lower lipid raft cholesterol concentration and impair signal 
transduction relevant to PCa progression (97). Experimental studies of how cells 
regulate cellular and raft cholesterol levels may provide new insight into the role 
of cholesterol in PCa and other tumors.  
 Liver X receptors (LXRs: LXRα and LXRβ) are transcription factors that 
regulate whole body cholesterol levels through transcriptional control of a number 
of key cholesterol metabolizing proteins and enzymes (8). Expression patterns of 
LXRα and LXRβ demonstrate that LXRα is primarily expressed in liver, adipose, 
and enterocytes where LXRβ is expressed ubiquitously (8).  The natural ligands 
for LXRα and LXRβ are oxygenated cholesterol intermediates such as 25-
hydroxycholesterol (25HC) and 24(S), 25- epoxycholesterol (24,25EC) known as 
oxysterols, which are derived from both cholesterol catabolism and synthesis, 
respectively (8). A highly specific synthetic LXR ligand T09 has also been 
developed (98). 
 In the liver, activation of LXRα by oxysterols results in the catabolism of 
cholesterol by increasing expression of the rate limiting enzyme in bile acid 
synthesis, CYP3A4 (CYP7A1 in mice) and hepatic-biliary duct transporters 
ABCG5 and ABCG8 (14). LXRα activation also increases the expression of 
ABCA1, which is involved in hepatic export of circulating cholesterol acceptor 
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protein apo A-I (14). In macrophages and peripheral tissue, oxysterol activation of 
LXRα or LXRβ increases the mRNA and protein expression of reverse 
cholesterol transporters ABCA1, ABCG1 and the lipid acceptor apo E (14). 
Excessive cellular cholesterol, derived from either d  novo synthesis or uptake 
from circulating low density lipoproteins (LDL), is removed from macrophages 
and peripheral cells by either non-energy dependant mechanisms or by energy 
dependant ABCA1, ABCG1 and circulating lipoprotein particles in a process 
called reverse cholesterol transport (RCT) that is chiefly regulated by LXRs (14). 
RCT is the major pathway involved in removal of excess cholesterol from 
peripheral tissue and has been shown to involve removal of cholesterol 
specifically from lipid raft domains.  
 Natural and synthetic LXR ligands also possess an anti-cancer effect on 
PCa and other cancers types in vitro and in animal studies, making LXR a 
potentially new therapeutic target in PCa and other tumors where plasma and 
intra-tumoral cholesterol levels are positively associated with advanced dis ase. 
Therefore studies examining whether RCT involving LXR and ABCA1 is 
functional in transformed PCa cells and whether RCT can alter cholesterol 
content of PCa cells and their lipid raft domains are warranted.  
 In light of the heterogeneity between LXRα and LXRβ signaling in other 
cell types, and the link between tumor cholesterol levels and advanced PCa, 
studies from this chapter sought to identify the relevant LXR isotypes and ligand 
behavior of T09, 25HC, and 24,25EC in the regulation of ABCA1 and ABCG1 
mRNA in two models of transformed prostatic epithelial cells - LNCaP and PC-3.  
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This study also sought to explore whether LXR-ABCA1 driven RCT is functional 
in PCa cells and whether cholesterol efflux in these cells results in changes to 
cellular free cholesterol concentrations and to lipid raft domains.  
Specific Hypotheses Tested    
Studies will be performed on androgen responsive LNCaP and non-androgen 
responsive PC-3 prostate cancer epithelial cells to examine the following 
hypotheses relating to LXR biology: 
a) To test the hypothesis that ABCG1 and LXRβ mRNA levels are higher than 
ABCA1 and LXRα respectively in both LNCaP and PC-3.  
b) To test the hypothesis that LXRβ and not LXRα is the primary regulator of 
mRNA levels of the cholesterol transporters ABCA1 and ABCG1 in LNCaP 
and PC-3 cells.  
c) To test the hypothesis that LXR mediated cholesterol efflux is functional in 
PC-3 cells.  
d) To test the hypothesis that LXR mediated cholesterol efflux alters intracellular 
free cholesterol or cholesteryl-esters in PCa cells.  
e) To test the hypothesis that LXR mediated cholesterol efflux can alter 
cholesterol rich plasma membrane raft domains in PCa cells.   
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ABSTRACT 
Recent evidence suggests that the liver X receptor (LXR) is a potential 
anti-cancer target in prostate carcinoma. There is little characterization, however, 
of which of the two LXR isoforms, LXRα or LXRβ, regulates the LXR-
responsive genes ATP-binding cassette sub-family members A 1 (ABCA1) and G 
1 (ABCG1) in transformed prostatic epithelial cells. In this study, small interfering 
RNA (siRNA) was used to determine whether LXRα or LXRβ is involved in 
regulating ABCA1 and ABCG1 mRNA expression in LNCaP and PC-3 cells. 
Treatment of both cell lines with the synthetic LXR ligand T09 and oxysterols: 
25-hydroxycholesterol (25HC) and 24(S), 25-epoxycholesterol (24,25EC), 
resulted in more than a 10-fold increase of ABCA1 and ABCG1 mRNA 
expression. Transfection of LNCaP cells with siRNA against either LXRβ or 
LXRα failed to inhibit T09 and 25HC-mediated increase of ABCA1 mRNA. 
siRNA silencing of LXRβ did, however, inhibit ABCA1 mRNA expression in 24, 
25EC-treated LNCaP cells. In contrast, LXRß siRNA inhibited T09, 25HC, and 
24, 25EC induction of ABCA1 mRNA in PC-3 cells and ABCG1 mRNA in both 
LNCaP and PC-3 cells. Additional experiments revealed that T09 and 25HC 
induction of ABCA1 mRNA expression was significantly inhibited by the p38 
stress kinase antagonist SB203580 and PKA inhibitor H89. However, siRNA 
studies against p38α/β and PKA revealed that p38 does not appear to be involved 
in T09 mediated regulation of ABCA1 mRNA in LNCaP cells, but PKA is 
involved in T09 regulation of ABCA1 mRNA in PC-3 cells. Treatment of PC-3 
cells with 1 µM of T09 resulted in cholesterol efflux to apo A-I and a decrease in 
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cellular free cholesterol levels. This effect was not observed in LNCaP cells under 
the same efflux conditions. Analysis of fluorescence images of PC-3 lipid raft 
domains revealed that LXR mediated RCT resulted in a significant decrease in 
cholesterol rich lipid raft domains only in the presence of the cholesterol acceptor 
apo A-I.  
MATERIALS AND METHODS 
Chemicals and Reagents 
Dharmacon ON-TARGETplus SMARTpool siRNA reagents targeting 
LXRα (Dharmacon Catalog # L-003413-00) or LXRβ (NM_007121) (Dharmacon 
Catalog # L-003412-00) , androgen receptor (AR) (Dharmacon Catalog # L-
003400), MAPK11(p38β) (Dharmacon Catalog # L-003972), MAPK14(p38α) ) 
(Dharmacon Catalog # L-003512), and PKA(cyclic AMP-dependent Protein 
Kinase A catalytic subunit a) (Dharmacon Catalog # L-004649) were purchased 
from Thermo Fisher Scientific (Lafayette, CO). HiPerFect Transfection Reagent 
was purchased from Qiagen (Santa Clarita, CA).  The selective inhibitors for 
p38α/β (SB203580), c-Jun N-terminal kinase (JNK) (SP600125), extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) (PD98059), cAMP dependent-protein 
kinase A (PKA) (H89), the LXR ligand 24(S),25-epoxycholesterol, and the 
synthetic pregnane x receptor (PXR) ligand (SR12813), were all purchased from 
BIOMOL International (Plymouth Meeting, PA). The synthetic LXR ligand T09 
was purchased from Cayman Chemical Company, (Ann Arbor, MI). 25-
hydroxycholesterol, dimethylsulfoxide (DMSO) and, human purified apo A-I 
were purchased from Sigma Chemical Co (St. Louis, MO). [1α,2α (n)-H3] tritium 
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labeled cholesterol was purchased from Perkin Elmer (Waltham, MA).  Amplex 
red cholesterol analysis kit and Vybrant ® Lipid Raft Labeling Kit were 
purchased from Invitrogen (Carlsbad, CA). 
Cell Culture 
The human prostate cancer cell lines LNCaP and PC-3 were purchased 
from the American Type Culture Collection (Manassas, VA) and maintained in 
RPMI-1640 medium Invitrogen (Carlsbad, CA), supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen, Carlsbad, CA), 1% glutamine, 100 U/mL 
penicillin, and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA) (culture 
medium). Cells were incubated in the presence of 5% carbon dioxide and air at 37 
°C. 
RNA Isolation and Real-Time Reverse Transcriptase Polymerase Chain 
Reaction (RT- PCR) 
For gene expression experiments, LNCaP and PC-3 cells were seeded in 6 well 
plates at a density of  0.5 x 106 cells/well and grown for 24 h in culture medium, 
then treated with various concentrations (0.1-10 µM) of 25HC, 24,25EC, T09, or 
vehicle (DMSO 0.05% v/v). After termination of experiments total RNA was 
isolated using the TRIzol® reagent (Invitrogen, Carlsbad, CA), and reverse 
transcribed to complementary DNA (cDNA) using StrataScript® First St and 
cDNA Synthesis Kit (Stratagene, La Jolla, CA). Real time PCR was carried out 
using a TaqMan Universal PCR Master Mix on an ABI Prism 7000 and TaqMan 
Fast Master Mix on a 7900 Sequence Detection System (Applied Biosystems, 
Foster City, CA). The TaqMan probes and primers were purchased from Applied 
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Biosystems using inventoried TaqMan gene expression assays: LXRα, (assay ID: 
Hs00172885_m1), LXRβ (assay ID: Hs00173195_m1), ABCG1 (assay ID: 
Hs00245154_m1), ABCA1 (assay ID: Hs01059122_m1), CYP3A4 (assay ID: 
Hs01546612), CYP3A5 (assay ID: Hs00241417), MDR1 (assay ID: Hs00184500), 
PPARα (assay ID: Hs00947537_m1), PPARγ (assay ID: Hs01115513_m1), 
CYP26A1 (assay ID: Hs00175627_m1), VDR (assay ID: Hs01045840_m1), 
HMGCR (assay ID: Hs00168352_m1), SQS(assay ID: Hs00926054_m1), LDLR 
(assay ID: Hs00181192_m1), SREBP1(assay ID: Hs01088691_m1), SREBP2 
(assay ID:Hs01081784_m1), CYP27A1 (assay ID: Hs01026016_m1), CH25H 
(assay ID:Hs02379634_s1), human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (assay ID: Hs99999905) was used as an endogenous control for all 
gene expression except for basal mRNA quantitation in Figure 2, where 18S 
ribosomal RNA (18S rRNA) (assay ID: Hs99999901) was used as an additional 
control. The following amplification parameters were used for gene expression on 
the ABI 7000: 50°C for 2 min, 95°C for 10 min, followed by 46 cycles of 
amplification at 95°C for 15 sec and 60°C for 1 min and on the ABI 7900: 95°C 
20 sec followed by 46 cycles of amplification at 95°C for 1 sec and 60°C for 20 
sec. Quantitation of mRNA fold changes were derived using the delta threshold 
cycle (∆Ct) method (84). 
Quantitation of Basal mRNA levels  
 The largest ∆Ct value of one gene was assigned as the control and 
normalized the lower ∆Ct value of the second gene to determine a comparative 
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∆∆Ct value. LXRβ ∆Ct values were normalized to LXRα ∆Ct values (control), and 
ABCG1 ∆Ct values were normalized to ABCA1 ∆Ct values (control). 
Quantitation of Comparative Basal mRNA Levels 
 The higher LNCaP cells ∆Ct values of each gene was assigned as the 
control and normalized the lower ∆Ct value of corresponding genes in PC-3 cells 
to determine a comparative ∆∆Ct value. ∆Ct values for LXRα and LXRβ in PC-3 
cells were normalized to LXRα and LXRβ ∆Ct values in LNCaP cells and ∆Ct 
values for ABCA1 and ABCG1 in PC-3 cells were normalized to ∆Ct values for 
ABCA1, ABCG1 in LNCaP cells. 
Cell Transfection with Small Interfering RNA (siRNA) 
LNCaP and PC-3 cells were seeded in 6-well plates at a density of 0.2 x 
106 cells/well and grown for 24 h in culture medium; then cells were switched to 
serum free media in RPMI-1640 (without phenol red) containing 2.0 mM L-
glutamine and 1% penicillin/streptomycin (serum-free culture medium). Cells
were transfected with Dharmacon ON-TARGETplus SMARTpool siRNA 
oligonucleotides using the HiPerFect liposomal transfection reagent (Qiagen) 
according to the manufacturer’s protocol. Preliminary experiments were 
conducted for each gene target to determine optimal transfection conditions 
without cytotoxicity. The concentrations of siRNA oligonucleotides used for each 
target were: 5 nM siRNA oligonucleotides for LXRα, LXRβ and androgen 
receptor (AR), 100 nM siRNA oligonucleotides for p38α, p38β and 25 nM for 
cyclic AMP-dependent PKA, catalytic subunit a (PKACa).  After 48 h of siRNA 
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transfection, cells were switched back to culture medium and treated with various 
ligands as described in Materials and Methods for an additional 48 h.  
Kinase Inhibitor Experiments 
For kinase inhibition experiments, LNCaP and PC-3 cells were plated in 
6-well plates as described above and pre-treated for 60 minutes with 10 µM of 
one of the following: the p38 MAP kinase inhibitor SB203580, the JNK MAP 
kinase inhibitor SP600125, the ERK1/2 MAP kinase inhibitor PD98059, the PKA 
inhibitor H89 or vehicle (DMSO 0.05% v/v). After 60 minutes cell culture media 
was replaced and cells were stimulated with 5 µM T09, 25HC, or 24,25EC for an 
additional 24 h.  
 Cholesterol Efflux Assay 
 PC-3 cells were plated in 10% fetal bovine serum (FBS) in triplicate and 
loaded with 1µCi/mL of [3H] labeled cholesterol (Perkin Elmer) for 48 h. After 48 
h PC-3 cells were washed thrice with PBS and switched to serum free conditions 
(RPMI 1640 (phenol free) + 0.2% fatty acid free bovine serum albumin (BSA) 
w/v). Cells were allowed 2 h to equilibrate cellular cholesterol in serum free 
conditions, washed thrice with PBS and treated for 48 h with either vehicle 
(DMSO 0.01% v/v) or 1 µM of the LXR ligand T09. After 48 h PC-3 cells were 
washed thrice with PBS + 0.2% BSA and incubated with either RPMI + 0.2% 
BSA plus 20 µg/mL of the cholesterol carrier apo A-I or vehicle (1X PBS) to 
initiate cholesterol efflux. Aliquots of 100 ul were collected at multiple time 
points for 24 h, mixed with scintillation liquid and measured for radioactivity on a 
scintillation counter. After 24 h cells were lysed with RIPA buffer (Thermo) and 
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protein measured using the bicinchoninic acid (BCA) assay (Thermo) according 
to the manufactures’ protocol. Efflux of vehicle treated cells will be subtracted 
from efflux of all groups as background and efflux will be expressed as counts per 
minute (CPM) of radioactivity in the cell culture medium per milligram of cellular 
protein. Mean differences in efflux between T09 + apo A-I and apo A-I alone will 
be measured at time points within the linear range.  
Gene Expression and Cellular Cholesterol Quantitation During Efflux 
 To analyze cellular cholesterol profile and gene expression during 
cholesterol efflux, PC-3 cells were plated under the same conditions as chole terol 
efflux experiments except tritium cholesterol loading was excluded. After48 h of 
cholesterol loading in 10% FBS, cells were washed and switched to serum fre 
medium as previously described and treated for 48 h. with 1 uM T09. After 48 h 
cells were washed with PBS and treated with either; vehicle (1X PBS), 5ug/mL 
for 4 h or 20 µg/mL apo A-I for 4 and 12 h. At time points of interest total cellular 
cholesterol or total RNA were isolated as described in the materials and methods 
section above. For total cellular cholesterol, lipids were extracted using the Folch 
method as previously described (99). Briefly, after termination of experiments 
cells were lysed with cold RIPA buffer (Thermo) using 1 mL of RIPA per 107 
cells.  Cell homogenates were sonicated at 50% intensity for 30 seconds on ice 
followed by incubation for 30 minutes on ice. Lipids were then extracted from 
aliquots of cell homogenates using chloroform: methanol (2:1). Organic phase 
solvents were evaporate from lipid extracts under nitrogen gas and resuspend in 
0.5% v/v Triton X-100 solution in water. Total and free cholesterol were 
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determined enzymatically using Amplex red cholesterol quantitation kit 
(Invitrogen) according to the manufactures protocol. Cellular cholesterol content 
was normalized to whole cell lysate protein concentrations. Protein was 
determined using the acid (BCA) assay (Thermo).   
Fluorescent Staining of Cholesterol Rich Membrane Domains  
 After treatments cells were washed three times in 1X PBS and incubated 
with 1µg/mL alexa flour conjugated cholera toxin subunit B (AF-CT-B) in 1X 
PBS for 10 minutes at 4 °C. Cells were then washed three times with 1 X PBS 
followed by incubation with 1 mg/mL anti-cholera toxin subunit B antibody 
(anti.CT-B) for 10 minutes at 4 °C. Cells were then washed thrice in 1X PBS and 
then counter stained with the nuclear fluorescent stain Hoechst 33258. Cells were 
mounted on microscopic slides and rafts visualized by a Nikon TE-2000-S 
fluorescence microscope. x and y coordinates for 10 random micrograph fields 
were derived from random numbers. Lipid raft positive cells were identified using 
a signal to noise ratio cut off of 7 based on the florescence intensity of control 
cells. Lipid raft positive cells were normalized as percent of total number of 
nuclei positive cells in each field. All imaged were analyzed using Nikon NIS 
elements imaging software version 3.2 (Nikon Inc., Hempstead, NY).  
Statistics 
 Statistical analysis of data will be carried out with the GraphPad PRISM 4 
program (GraphPad Software, Inc.). Contrasts of group means were computed 
using one or two factor ANOVA followed by Bonferroni post hoc tests. The 
unpaired Student's unpaired t test was used to compare experiments between two 
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groups. Gene expression results is expressed as means ± SE of comparative fold 
differences. Mean differences of post-hoc analyses are considered significant 
when p value is < 0.05.  
RESULTS 
Specificity of the Synthetic LXR ligand T09 in PCa Cells 
To determine the specificity T09 in LNCaP and PC-3 cells, mRNA 
expression of a panel of NRs and NR responsive genes were measured in LNCaP 
and PC-3 cells treated with 10µM of T09 for 48 h. Figure 1 demonstrates that 
treatment of both cell lines with T09 resulted in specific transcriptional increases 
in LXR target genes ABCA1 and ABCG1, while the mRNA expression of the 
nuclear receptors PPARγ, VDR were unchanged compared to vehicle controls (Fig 
1). There was a ~80% significant decrease in mRNA expression of PPARα, in 
PC-3 cells treated with T09 compared to vehicle treated controls (p < 0.01).  
mRNA levels for the specific target genes of PXR (CYP3A4 and MDR-1) and 
RARs (CYP26A1) were also unaffected by treatment with pharmacological 
concentrations of the LXR ligand T09 (Fig 1).  
Basal Levels of LXR and Cholesterol Metabolism genes in PCa Cells  
PC-3 cells are bone derived metastatic PCa cells and do not rely on 
steroids for maintenance of their growth program, where LNCaP cells do. PC-3 
cells have been characterized as a more aggressive phenotype of PCa compared to 
LNCaP cells, and as bone metastasized cells, PC-3 cells represent a stage of PCa 
most difficult to treat in men. Human studies demonstrated that cholesterol levels 
are linked only to late stage advanced PCa; therefore it was examined whether 
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PC-3 cells express higher basal levels of LXR and cholesterol metabolism related 
genes compared to the less aggressive LNCaP cells. Also total levels of fre
cholesterol and cholesteryl-esters were compared in both cell types.  
As shown in Figure 2A and 2B, the data revealed that basal mRNA levels 
of LXRβ were significantly higher than LXRα in both LNCaP and PC-3 cells, as 
were basal levels of ABCG1 compared to ABCA1. Across the cell types, PC-3 
cells expressed significantly higher basal levels of all genes with an exceptionally 
higher expression of ABCA1 mRNA (Fig. 2C and 2D).   
 To determine whether PC-3 cells express higher mRNA levels of a 
number of other key cholesterol metabolism related genes, basal mRNA levels of 
genes related to cholesterol synthesis and uptake: HMGR, SREBP2, FNTA, SQS 
LDLR, triglyceride synthesis: SREBP1, and cholesterol degradation CYP27A1  
CH25H were determined.  Gene expression revealed that PC-3 cells express 
significantly higher basal mRNA levels of SREBP1, SREBP2, HMGR, LDLR and 
SQS compared to LNCaP cells (Fig 2E). Basal levels of two key enzymes 
involved in cholesterol degradation and genesis of LXR ligands CYP27A1 and 
CH25H were lower in PC-3 cells compared to LNCaP; however this difference 
was not significant (p > 0.05, Fig 2E).  
Cholesterol Profile of PC-3 and LNCaP cells  
  Analysis of free cholesterol and cholesteryl-esters levels in PC-3 and 
LNCaP demonstrated that free cholesterol levels were approximately two fold 
higher in PC-3 cells compared to LNCaP after being cultured for 48 h in 10% 
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FBS (p < 0.001, Fig 2F).  Levels of cholesteryl-esters were not detectable in either 
cell type (Fig 2F).  
Concentration Effects of LXR Ligands on ABCG1 and ABCA1 mRNA 
Expression  
To measure the concentration effects of synthetic and natural LXR ligands 
on mRNA expression of ABCA1 and ABCG1, LNCaP and PC-3 cells were treated 
with increasing concentrations (0.1-10 µM) of T09, 24,25EC, and 25HC for 24 h. 
In both LNCaP (Fig. 3A and 3B) and PC-3 cells (Fig. 3C and 3D), treatments 
with T09, 25HC, and 24,25EC resulted in dose responses in ABCA1 and ABCG1 
mRNA expression. LNCaP cells treated with the synthetic LXR ligand T09 
resulted in a ~4 to 20-fold induction of ABCA1 mRNA compared to ~4 to 10-fold 
inductions in 24,25EC and in 25HC treated cells (Fig. 3A). ABCG1 mRNA fold 
induction in T09 treated LNCaP cells was ~9 to 20-fold compared to ~2 to 8-fold 
in oxysterol treated cells (Fig. 3B). PC-3 cells treated with increasing 
concentrations of T09 resulted in a ~12 to 25-fold induction of ABCA1 mRNA 
compared to 2 to 7-fold inductions in 24,25EC and 25HC treated cells (Fig. 3C). 
In a similar manner to ABCA1, ABCG1 mRNA fold induction in T09 treated PC-3 
cells was ~8 to 15-fold compared to ~2 to 6-fold in 24,25EC and 25HC treated 
cells (Fig. 3D).  Between PC-3 and LNCaP cells,  a significantly stronger ABCA1 
mRNA induction in PC-3 cells specifically within the T09 concentration range of 
0.1 and 1.0 µM was observed (~10 to 20-fold in PC-3 vs. ~3 to 5-fold in LNCaP) 
(Fig. 3A and 3C). In PC-3 cells, the concentration plateau for T09 induction of 
ABCA1 mRNA began at 5 µM. In LNCaP cells, however, the dose- dependent 
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effect of T09 and all oxysterols was linear up to 10 µM. This trend was also 
observed for LXR ligand induction of ABCG1 mRNA in LNCaP and PC-3 cells. 
Fold changes for ABCG1 mRNA with increasing doses of all LXR ligands were 
similar in both LNCaP and PC-3 cells (Fig. 3B and 3D).  
Temporal Effects of LXR Ligands on ABCG1 and ABCA1 mRNA 
Expression 
Temporal changes in ABCA1 and ABCG1 mRNA expression were also 
determined by treating LNCaP and PC-3 cells with 5 µM of T09, 25HC, and 
24,25 EC for 2-24 h. Fig. 4A and 4B show a significantly earlier change in 
mRNA response of ABCA1 at 2 h compared to ABCG1 in LNCaP cells (~3-fold 
vs. 0-fold). The opposite effect was observed in PC-3 cells, with the change in 
ABCG1 mRNA increasing dramatically between 2 and 4 h by almost 10-fold, 
where ABCA1 mRNA changes were approximately 5-fold less in the same time 
frame (Fig. 4C and 4D).  
Ligand and LXR Isoform Specific Regulation of ABCA1 and ABCG1 mRNA 
Expression Varies between Cell Types 
 Given that both LXR isoforms are expressed in prostate cancer cells, 
experiments were conducted to determine whether LXRα or LXRβ are required 
for oxysterol- and T09- mediated induction of ABCA1 and ABCG1 mRNA using 
siRNA technology. siRNA transfection conditions resulted in ~70-80% silencing 
of LXRα and LXRβ mRNA expression levels in both LNCaP and PC-3 cells. In 
both cell lines, all LXR ligands significantly increased basal levels of LXRβ (Fig. 
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5A and 5B, Fig. 6A and 6B), but had no significant effect on LXRα mRNA levels. 
(Fig 5A and 5B, Fig 6A and 6B). 
Surprisingly, LNCaP cells transfected with either siRNA against LXRβ or 
LXRα could not inhibit T09 or 25HC induction of ABCA1 mRNA (Fig.5C and 
6C). Use of siRNA against LXRβ was able to inhibit ABCA1 mRNA in LNCaP 
cells treated with 24,25EC only (Fig. 6C). A significant inhibition of ABCG1 
mRNA induction by all LXR ligands in LNCaP cells transfected with LXRβ 
siRNA was observed (Fig. 6C); however LXRα siRNA had no effect on ABCG1 
mRNA induction by any LXR ligand (Fig. 5C). In PC-3 cells, T09 and oxysterol 
regulation of ABCG1 and ABCA1 mRNA expression was more straightforward. 
The use of siRNA against LXRß inhibited the mRNA expression of both ABCG1 
and ABCA1 in PC-3 cells exposed to T09, 25HC, and 24,25EC (Fig. 6D). siRNA 
against LXRα also had no effect on these targets in PC-3 cells (Fig. 6D).   
Involvement of Kinase Signaling in LXR ligand Regulation of ABCA1 mRNA 
in LNCaP and PC-3 Cells  
 In observing that neither LXRα nor LXRß appeared to be involved in T09 
or 25HC regulation of ABCA1 mRNA expression, a number of kinase pathways 
screened to determine whether T09 or 25HC can regulate ABCA1 mRNA 
expression through a non-LXR mediated pathway involving kinase signal 
transduction. LNCaP and PC-3 cells were pre-treated for 60 minutes with 10 µM
of each of the following specific kinase inhibitors: ERK1/2 (PD98059), PKA (H-
89), p38α/β (SB203580) or JNK (SP600125); they were then treated with and 
without 5 µM of T09 and 25HC for an additional 24 h. Pre-treatment of LNCaP 
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cells with the p38 antagonist SB203580 caused a ~45% inhibition of both T09 
and 25HC induction of ABCA1 mRNA expression (p <0.01) (Fig. 7A). This was 
specific to ABCA1 as there was no inhibition observed on ABCG1 mRNA levels 
(Fig. 7B). Inhibition of p38 in PC-3 cells only affected T09-mediated induction of 
ABCA1 mRNA (Fig. 7C), however unlike LNCaP cells, SB203580 also inhibited 
T09 mediated increase in ABCG1 mRNA levels by ~ 36% in PC-3 cells (Fig 7D).  
In contrast, inhibition of JNK kinase in both LNCaP and PC-3 cells resulted in a 
~6-fold induction of basal mRNA levels of ABCA1 (Fig. 7A and 7C).  Moreover, 
JNK inhibition produced an additive effect on T09- and 25HC-induced increase 
of ABCA1 mRNA in LNCaP cells (Fig. 7A). In PC-3 cells this effect was only 
observed for T09 induction of ABCA1 mRNA (Fig. 7C). In both cell lines, 
inhibition of ERK1/2 had no effect on mRNA expression of either ABCA1 or 
ABCG1 (Fig. 7A-D). Lastly, the PKA inhibitor H89 strongly opposed T09 
induction of ABCA1 mRNA in PC-3 cells, but had no effect on ABCG1 (Fig 7C 
and 7D).  
 To further test whether the pharmacological inhibition of LXR 
transcription of ABCA1 involved p38 in LNCaP and PKA in PC-3 cells, siRNA 
oligonucleotides were used to transiently silence expression of p38α, β in 
LNCaP cells and PKA in PC-3 cells treated with and without  5 µM of T09.  With 
two isoforms of p38, LNCaP cells were transfected concomitantly with siRNA 
oligonucleotides against p38α, and p38β. Optimal transfection conditions were 
determined to yield approximately 70-80% silencing of p38α, and p38β without 
any cytotoxicity or off target effects (Fig 8).  Contrary to the pharmacological 
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inhibition of LXR mediated transcription of ABCA1 that was observed with the 
pan p38 inhibitor SB203580, silencing expression of p38α, and p38β in LNCaP 
cells failed to oppose T09 mediated regulation of ABCA1 mRNA levels (Fig. 8), 
suggesting that SB203580 can interact with other kinases or protein targets.  
 Data from experiments with PC-3 cells transfected with siRNA 
oligonucleotides against the cAMP dependent kinase PKA demonstrated that 
PKA is involved in LXR regulation of ABCA1 in PC-3 cells. siRNA against the 
alpha catalytic unit of PKA significantly inhibited T09 mediated transcription of 
ABCA1 mRNA (Fig 9).  Also, PC-3 cells stimulated with the cAMP/PKA 
activator forskolin had significant increases in ABCA1 mRNA expression which 
were also opposed by PKA siRNA silencing (Fig 9). The involvement of PKA in 
regulating LXR mediated activation of ABCA1 mRNA does not appear to involve 
expression of LXRα or LXRß, as no changes to mRNA levels of these genes were 
observed in cells transfected with PKA siRNA (Fig 9).  Consistent with the 
pharmacological inhibitor studies using H89, siRNA against PKA did not 
opposed T09 regulation of ABCG1 mRNA levels (Fig 9).  
Cholesterol Efflux in PC-3 cells 
 Studies where carried out to establish whether LXR-ABCA1 mediated 
cholesterol efflux was functional in PC-3 cells. Studies of cholesterol efflux were 
also attempted in LNCaP cells, however due to the labile nature of LNCaP 
adhesion to the plastic cell culture plate surface, large cell losses were observed 
during efflux experiments due to the extensive washing steps required for the [3H] 
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cholesterol loading and efflux assay. Due to this experimental constraint, it was
not possible to objectively measure cholesterol efflux in this cells line.  
 PC-3 cells loaded with 1µCi/mL of tritium labeled cholesterol for 48 h 
followed by 48 h treatment with 1 uM of the LXR ligand T09 displayed a 
significant rate of cholesterol efflux at 2 h of upon exposure to apo A-I (Fig. 
10B).  Cells pre-treated with vehicle and apo A-I were able to efflux cholesterol, 
however this was not significantly higher than cells pre-treated with T09 without 
apo A-I. Under the present experimental conditions cholesterol efflux was 
initiated by 2 h and was linear up to ~6 h of exposure to apo A-I (Fig. 10A). Cells 
pre-treated with T09 alone did not show significant rates of cholesterol efflux 
demonstrating that efflux was dependant on the presence of apo A-I and therefore 
specific to LXR-ABCA1 mediated efflux. siRNA against LXRα or LXRβ were 
performed to determine which receptor isoform was involved in mediating 
cholesterol efflux from PC-3 cells. Optimal conditions for siRNA transfection of 
LXRα or LXRβ were determined in previous experiments and produced 80-90% 
silencing of these targets, however it was determined that the experimental 
conditions of cholesterol efflux, i.e. loading of cells with 1µCi/mL of tritiated 
cholesterol for 48 h in 10% FBS, was not sufficient to permit successful PC-3 
transfection with siRNA oligos against LXRα or LXRβ.  
Cholesterol Quantitation Prostate Cancer Epithelial Cells 
 To determine if LXR-ABCA1 mediated cholesterol efflux can leads to a 
decrease in cellular cholesterol levels in PC-3 cells during cholesterol efflux, PC-
3 cells were plated for RCT as described in material and methods and RCT 
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initiated with the addition of 5 and 20 µg/mL of apo A-I for 4 h and 12h. After 4h 
and 12 h total lipids were isolated and cholesteryl-esters and free cholesterol 
determined enzymatically. Figure 11A demonstrates that after 4 h of RCT, PC-3 
cells chased with 5 and 20 µg/mL apo A-I have significantly lower free 
cholesterol levels compared to cells only pre-treated with T09 alone. (Fig 11A). 
After 12 h of incubation with 20 µg/mL apo A-I free cholesterol levels in PC-3 
cells significantly increased compared to cells treated with apo A-I for 4 h 
(checked bars vs. solid black bar) suggesting a compensatory increase in cellular
cholesterol after RCT (Fig 11A). Cholesteryl-esters were not detectable in PC-3 
cells under any of the experimental conditions (Fig 11 A). Treatment with 1 µM 
of T09 for 48 h was unable to alter cellular cholesterol levels in PC-3 cells 
cultured with 10% fetal bovine serum (FBS) (Fig 11B); demonstrating that LXR-
ABCA1 mediated RCT result in changes in cellular free cholesterol levels in PC-3 
cells only in the presence of lipid free apo A-I.   
Cholesterol Metabolism Gene Signature of PC-3 cells during Efflux 
 To determine the gene expression changes during RCT a panel of genes 
related to LXR-mediated efflux, de novo cholesterol synthesis and cholesterol 
uptake were measured at 4h and 12 h after RCT conditions. After 4 h of 
cholesterol efflux, as expected, mRNA levels of ABCA1 and ABCG1 increased 
significantly in cells pre-treated with T09 compared to vehicle treated cell (Fig. 
11C and 11D), however in T09 + apo A-I chased cells the mRNA levels of 
ABCA1 and ABCG1 were significantly higher than in cells treated with T09 alone 
(p < 0.001 and p < 0.05 respectively). After 12 h of RCT ABCA1 mRNA levels 
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were significantly lower than at 4h of RCT, where ABCG1 mRNA levels were 
unchanged (Fig 11C and 11D).  Three genes central de novo cholesterol synthesis 
SREBP2, HMGR, and uptake of circulating cholesterol levels, low density 
lipoprotein receptor (LDLR), were also measured during cholesterol efflux at 4h 
and 12h. After 4 h of RCT there were no significant changes in SREBP2, HMGR 
and LDLR mRNA levels (Fig 11E-G).  After 12 h of RCT mRNA levels of 
SREBP2 and HMGR remained unchanged, however mRNA expression of LDLR 
significantly increased in T09 + apo A-I treated cells compared to vehicle and 
T09 treated cells (p  < 0.01, Fig 11G).   
Alexa Fluor Staining of Plasma Membrane Lipid Rafts  
 To determine whether LXR-ABCA1 mediated cholesterol efflux can alter 
plasma membrane lipid raft domains, PC-3 cells were labeled with the beta 
subunit of cholera toxin (Ct-b) conjugated to Alexa fluor. Ct-b binds with high 
affinity to lipid raft domains protein ganglioside gm1 (gm1) and anti-cholera 
antibodies induce co-patching of raft positive domains (100). This process is 
attenuated with perturbation to raft cholesterol level and is reflected in decreas d 
fluorescence intensity of Alexa fluor (100). Fluorescent micrographs of PC-3 cells 
demonstrated that formation of lipid raft domains were significantly diminished in 
T09 + apo A-I treated cells compared to T09 alone treated cells (p < 0.01, Fig 12), 
suggesting that that LXR-ABCA1 mediated cholesterol efflux can disrupt lipid 
raft formation. T09 pre-treatment alone also appeared to decrease the number of 
lipid raft positive cells, but this effect was not significant (p > 0.05 Fig 12). 
Collectively these findings suggest that increased ABCA1 gene expression, in 
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itself, can lead to early partitioning of cholesterol from raft to non-raft domains, 
but initiation of cholesterol efflux is necessary for significant disruption of raft 
domains in PC-3 cells.  
DISCUSSION   
 The recent emergence of data suggesting that LXR ligands activated an 
anti-cancer effect in models of prostate carcinoma prompted us to examine the 
regulation of LXR-mediated pathways in LNCaP and PC-3 human prostate cancer 
cells (65, 66). This study specifically sought to characterize in these transfo med 
epithelial cells which LXR isoform is involved in the transcriptional regulation of 
the LXR responsive genes ABCA1 and ABCG1. I hypothesized that the LXR 
regulatory mechanisms in these models of prostatic carcinoma would be distinct 
from other cell types and that a cell-specific response would have to be 
considered in any future studies of the anti-cancer effect of LXR ligands.  
Specificity of Synthetic LXR ligand T09 in PCa cells  
There is data demonstrating cross talk between NR with the type 2 family 
of NRTF (1). It was recently demonstrated that the synthetic LXR ligand T09 can 
activate PXR in other cell types (101).  In the cell types used in the current 
project, there was no evidence that the LXR ligand T09 activates PXR based on 
the absence of any mRNA changes to two known PXR responsive genes CYP3A4 
and MDR-1.  However, there was evidence that T09 can significantly reduce 
mRNA levels PPARα in PC-3 cells.  There were no other NR targets affected by 
T09 treatment in either LNCaP or PC-3. Nevertheless, despite the lack of any 
apparent interaction between T09/LXR and PXR in these cell types. Results from 
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experiments conducted using T09 in PC-3 cells should be weighed against any 
possible involvement of PPARα and the current experiment does reveal a lack of 
specificity of T09 in PC-3 cells when used at 10µM.   
PC-3 cells express higher levels of LXR and Cholesterol Metabolism Related 
Genes and Cholesterol Levels than LNCaP cells.  
 LXR isoform mRNA profiling determined that relative LXRβ mRNA 
expression is significantly higher than LXRα in both LNCaP and PC-3 cells. This 
did not come as a surprise as most expression profiling has determined that LXRα 
is primarily expressed in liver, adipose and enterocytes, where LXRβ is expressed 
ubiquitously (6, 7). Our LXRα and LXRβ mRNA profiling does conflict with a 
previous study which reported that LXRα is the predominant isoform in LNCaP 
cells and the ratio of LXRα to LXRβ in PC-3 cells is approximately one (102). We 
used a similar normalization method as this previous report (102), but found 
LXRβ to have higher relative mRNA levels in both LNCaP and PC-3 cells. 
Our basal mRNA measurements revealed disproportionally lower ABCA1 
mRNA expression compared to ABCG1 in both LNCaP and PC-3 cells. There is 
evidence in some cell types that without functional ABCA1, that ABCG1 alone is 
incapable of regulating the cholesterol efflux machinery due to the cooperative 
requirement of ABCA1 and apo A-I in formation of pre-HDL particles (18). 
Further support for a critical role of ABCA1 in HDL formation and cholesterol 
efflux come from observations of severe HDL deficiency and pathological 
cholesterol retention in persons with functional mutations of the ABCA1 gene 
(19). Carriers of ABCA1 mutations, such as those seen in Tangier disease, are 
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largely incapable of normal reverse cholesterol transport despite carrying normal 
copies of the ABCG1 gene (19).  If ABCA1 synergizes with ABCG1 for 
cholesterol removal in LNCaP and PC-3 cells as it does in other cell types, hen 
our data may have revealed a propensity for impaired cholesterol efflux in these 
transformed cell models. This would support a body of data demonstrating 
abnormal prostatic cholesterol retention in men with advanced PCa (61-64).  
A number of epidemiological studies have demonstrated that the 
association between cholesterol and PCa exists only for aggressive forms o PCa
(61-64). It is not clear why the association between cholesterol and PCa only 
appears in late stage and metastatic disease, but some data suggests that late stage, 
hormone refractory PCa is associated with increase the rate of cholesterol 
synthesis, possibly to support increased prostatic steroidogenesis (103). This may 
suggest that some metabolic genes involved in energy and lipid metabolism 
would be a poor predictor of those at risk for advanced disease, but therapies 
aimed at shifting the balance of cholesterol metabolism towards degradation and 
removal may have a positive outcome of these aggressive stages of disease. There 
is already epidemiological data supporting that either drug therapy through use of 
statins or lifestyle to control serum cholesterol levels protects against aggressive, 
late stage PCa (61-64). In the current study, the two cell models used, LNCaP and 
PC-3 have origins which link them to two clinically discrete stages and grades of 
PCa. PC-3 cells are derived from grade IV, hormone refractive PCa bone 
metastasis and display a more aggressive phenotype (33 h doubling time in nude 
mice), and LNCaP cells isolated from lymph nodes of metastatic hormone 
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sensitive PCa are relatively less aggressive (88 h doubling time in nude mice) 
(104).  Expression patterns of genes central to the LXR axis and de ovo 
cholesterol synthesis revealed that PC-3 cells expression disproportionately high r 
levels of LXRα, LXRβ, ABCA1 and ABCG1 compared to LNCaP cells. The 
relative difference was most striking for ABCA1 which had almost a 20 fold 
greater mRNA level. Expression of genes related to cholesterol SREBP2, HMGR 
and SQS and triglyceride synthesis SREBP1 where also significantly higher in 
PC-3 cells. Expression of two genes central to oxysterol synthesis, CYP27A1 and 
CH25H, were lower in PC-3 cells, but this was not significant.  Cholesterol 
analysis also revealed that PC-3 cells contain significantly higher levls of free 
cholesterol compared to LNCaP. This observation supports data demonstrating 
that PC-3 cell basal cholesterol synthesis is higher than LNCaP cells and are more 
sensitively to sterol deprivation that LNCaP cells (105). Despite having 
significantly higher levels of LXR responsive genes, ABCA1 and ABCG1 than 
LNCaP, free cholesterol levels in PC-3 cells still remain higher than LNCaP, 
suggesting that the net cholesterol turnover remains lower in the more aggressive 
cell type. Nevertheless, it is not clear if the higher aggrieves phenotype of PC-3 
cells and its higher rate of cholesterol synthesis are related, and studies to 
determine this relationship are needed.  
Expression Data from NCBI Gene Expression Omnibus Database 
 To further examine whether the ABCA1, ABCG1 mRNA ratio profile in 
these transformed cell lines differs to those found in normal prostate epithelial 
cells, a query was performed using the National Center for Biotechnology 
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Information’s (NCBI) Gene Expression Omnibus database 
www.ncbi.nlm.nih.gov/projects/geo (106). We found in two separate array 
profiles of normal prostate epithelial cells that ABCA1 mRNA expression was 
approximately 2 to 3-times greater than ABCG1 (GEO accessions: GDS1746 (37), 
GDS1973 (38). We also found expression profile data in GEO accession: 
GDS1746 which demonstrated that, similar to our findings, a low ABCA1, 
ABCG1 mRNA ratio exists in LNCaP cells. Collectively, these data strongly 
suggested that the ABCA1, ABCG1 mRNA expression ratio is decreased in 
transformed prostatic epithelial cells and supported data demonstrating abnorm l 
prostatic cholesterol retention in PCa (61). Due to the integral role that LXR and 
ABCA1 have in cholesterol efflux, it is warranted to determine whether 
suppression of LXR-ABCA1 function is another mechanism through which 
transformed prostatic cells can increase their cholesterol pool.  
Involvement of LXRβ is dependant on Target and Ligand Tested  
Data from our siRNA experiments supported our original hypothesis that 
LXR biology in these transformed cells would be atypical. We found that the 
synthetic and natural LXR ligands T09, 25HC, and 24,25EC showed distinct LXR 
dependent and independent regulation of ABCA1 mRNA in both LNCaP and PC-
3 cells. The discovery that siRNA against LXRα or LXRß failed to inhibit T09- 
and 25HC-mediated ABCA1 mRNA induction in LNCaP cells was compelling 
and contrasts with reports from numerous LXR functional studies demonstrating 
that T09 and oxysterols are potent LXR ligands and increase ABCA1 mRNA 
expression through direct ligand activation of LXR (107).  Although there are 
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reports in macrophages and skin fibroblasts that T09 can also activate the 
xenobiotic transcription factor PXR, we found that LNCaP and PC-3 cells treated 
for 24 h with multiple concentrations of T09 had no effect on expression of the 
PXR responsive genes CYP3A4, CYP3A5 and MDR-1. We also did not observe 
any ABCA1 and ABCG1 mRNA changes in cells treated with multiple 
concentrations of the PXR agonist SR12813. These experiments support that T09 
induction of ABCA1 and ABCG1 mRNA is not mediated through PXR in LNCaP 
or PC-3 cells.  
These experiments revealed that, in comparison to other ligands tested, 
24,25EC uniquely required LXRß in regulating both ABCA1 and ABCG1 mRNA 
expression in LNCaP cells. 24,25EC is synthesized exclusively in a shunt reaction 
from the mevalonate de novo cholesterol synthesis pathway and is believed to 
permit cellular sensing of excess cholesterol biosynthesis (108).  
It was observed that ABCG1 mRNA regulation by synthetic and natural 
LXR ligands in LNCaP cells strongly required the expression of LXRß. This was 
also observed for ABCG1 and ABCA1 mRNA expression in PC-3 cells transfected 
with siRNA against LXRß.   The lack of a consistent involvement of LXRß in 
ligand induction of ABCA1 mRNA in LNCaP cells likely reflected the numerous 
molecular distinctions between these two cells lines (104, 110). The most 
prominent difference is the lack of functional AR and the need for androgen-
driven growth in PC-3 cells, which is suggestive of a relevant cross-talk between 
androgen and LXR signaling in LNCaP cells (110). It has been reported in 
LNCaP cells that androgens strongly suppress the expression of ABCA1, and that 
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T09 can act as an anti-androgen (102, 111). Conversely, the regulation of ABCG1 
mRNA by synthetic and natural LXR ligands in both LNCaP and PC-3 cells is 
consistent with reports that ABCG1 mRNA transcriptional regulation comes 
exclusively under LXR (112). Given that our siRNA transfections against LXRα 
and LXRß achieved 70-80% silencing of these genes, our data strongly support a 
principal role of LXRß but not LXRα in the regulation of induction of ABCA1 and 
ABCG1 mRNA by T09 and oxysterols in these models.  
The Stress kinase p38 is not involved in regulation of ABCA1 in LNCaP cells 
Our pharmacological inhibitor studies initially suggest that T09 and 25HC 
regulation of ABCA1 mRNA expression may involve the kinases-mediated 
pathway of p38, JNK and PKA. Both p38 and JNK mediate the cellular stress 
response and are naturally activated by a variety of stimuli including pro-
inflammatory cytokines, osmotic shock and ultraviolet irradiation (113). There is 
a report of TNF-α induction of ABCA1 mRNA expression in mouse peritoneal 
macrophages through the stress kinase p38 (114).  Nevertheless, the p38 
antagonist used in our experiments, SB203580, has been shown to also activate 
JNK and the ERK1/2 map kinase pathway (115, 116).  The pleiotropic effect of 
SB203580 raised the possibility that its inhibitory effect on T09 and 25HC 
induction of ABCA1 mRNA could occur through uncharacterized targets other 
than p38.   
To add complexity to the regulation of ABCA1 mRNA, we also observed 
that inhibition of JNK with SP600125 raised basal and LXR ligand inducible 
levels of ABCA1 mRNA ~6 and 1.5-fold respectively in both LNCaP and PC-3 
 60
cells (Fig 7A and Fig 7B).  Both p38 and JNK are typically redundant members of 
the stress-activated protein kinase pathway; however it has been shown that they 
can oppose each other depending on the downstream target (117). The observed 
induction of ABCA1 mRNA by the JNK inhibitor could reflect a similar 
antagonism of JNK towards p38 signaling and could represent be a molecular 
“on” and “off” of ABCA1 gene regulation.   We observed a similar effect on 
ABCA1 mRNA response in PC-3 cells pre-treated with p38 and JNK inhibitors 
supporting a common regulation of ABCA1 gene expression by a signal 
transduction pathway in both LNCaP and PC-3 cells.  
siRNA experiments confirmed that p38 does not appear to be required in 
T09 regulation of ABCA1 or ABCG1 mRNA levels in LNCaP cells. To exclude 
the possibility that SB203580 was acting through a specific p38 isoform, LNCaP 
cells where transfected with a pool of siRNA oligonucleotides ensuring targeting 
of both p38α and p38β. Despite the observed inhibitory effect of use of this 
pharmacological inhibitor, data from these siRNA experiments contradict the 
pharmacological inhibition that was observed with SB203580 and illustrates the 
potential for pleiotropic effects of pharmacological inhibitors when targeting 
disruption of signal transduction pathways.  
PKA is involved in regulation of ABCA1 in PC-3 cells.  
  Pharmacological inhibition of PKA with H89 strongly opposed T09 
induction of ABCA1 mRNA. However, unlike our experiments using p38 siRNA, 
transfection of PC-3 cells with siRNA oligonucleotides against PKA confirmed 
the involvement of PKA in this pathway. PC-3 cells treated with the cAMP 
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agonist and PKA activator forskolin resulted in significant upregulation of ABCA1 
mRNA levels but not ABCG1. This was reverse by siRNA against PKA 
confirming that PKA can upregulate ABCA1 in the absence of LXR ligand 
activation. This data is consistent with studies demonstrating that cAMP/PKA 
activation leads to upregulation of ABCA1 mRNA, protein phosphorylation and 
cholesterol efflux in macrophages and lipid loaded fibroblasts (118). cAMP/PKA 
is activated by apo A-I in macrophages and leads to increased ABCA1 mRNA 
expression and stabilization of protein levels via serine phosphorylation (119). 
PKA activation and stabilization of ABCA1 initiates and enhances cholesterol 
efflux even in the absence of LXR ligands (119). Our data are consistent with 
studies demonstrating a role for PKA in LXR mediated activation of ABCA1 and 
regulation of basal ABCA1 mRNA levels (119). The observed differences in 
regulation of ABCA1 mRNA between PC-3 and LNCaP are likely a consequence 
of the many molecular distinctions between these two cell types and warrants 
further testing.  
LXR mediated cholesterol efflux decreases plasma membrane cholesterol 
raft domains.  
 Studies in lipid laden macrophage foam cells demonstrate that LXR 
activation shifts the dynamic balance of cholesterol metabolism towards efflux 
resulting in decreased cellular cholesterol levels and attenuation of foam cell 
development.  Experimental data suggests that transformed prostate tumors have 
increased cholesterol levels compared to begin or normal prostatic tissue, 
demonstrating that the balance of cholesterol metabolism (synthesis/uptake and 
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degradation/efflux) shifts towards increases retention, but it is not clear which
side of the dynamic regulation of intracellular cholesterol is altered in late st ge 
PCa (61). There is some data demonstrating a discrete upregulation of de vo 
cholesterol synthesis in men with hormone refractory resistant PCa (103), but this 
may reflect a specific shift to prostatic cholesterol-steroid synthesis in response to 
castration. Prostatic tissue, like many peripheral tissue, preferentially derive 
cholesterol from circulating lipoproteins, this supports the population data 
demonstrating a positive  correlation between risk of advanced PCa and serum 
cholesterol levels (61-64). However, all cells in peripheral tissue possess the 
machinery to remove excesses cellular cholesterol through reverse cholesterol 
transport mediated by LXR-ABCA1 (18). There is an information gap on whether 
the efflux side of the cholesterol metabolic equation is compromised in advanced 
PCa and equally important, whether increases cholesterol efflux can alter 
intracellular cholesterol levels. This is vital to understand the role of cholesterol in 
carcinogenesis and to aid in developing adjuvant therapies that can compliment 
the current belief that lifestyle and/or use of cholesterol synthesis inhibitors can 
protect against advanced PCa.  
 This project demonstrated that LXR mediated cholesterol efflux is active 
in PC-3 cells.  PCR analysis demonstrated that the gene expression fingerprint 
during cholesterol efflux showed a strong increase in ABCA1 mRNA levels, but a 
dramatic induction of ABCG1 mRNA (~130 fold), a level not previously observed 
in PC-3 or LNCaP cells. The hyper-augmented ABCG1 mRNA levels might 
reflect higher ABCG1 protein as ABCA1 increased synthesis of immature HDL 
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particles from apo A-I. ABCA1 is considered the rate limiting step in HDL 
synthesis, allowing immature HDL particles to specifically interact with ABCG1 
and continue cholesterol removal (18).  
 Examining cellular cholesterol levels during efflux stimulation revealed 
that cholesterol efflux was associated with a significant dose dependant apo A-I 
decrease in free cholesterol levels. The decrease in cellular cholesterol was 
observed after 4 hr of efflux but appears to be reversed by 12 h. This pattern of 
changes to cellular cholesterol levels corresponds to 4-6 h of linear cholesterol 
efflux typically observed under the current protocol. The changes in cellular 
cholesterol levels may not be a true reflection of the cellular response to LXR 
mediated efflux as serum free culture conditions deprive cells access to serum 
cholesterol to response to the shift towards cholesterol removal.  
 Analysis of genes related to de novo cholesterol synthesis and uptake 
revealed that under the efflux conditions, PC-3 cells did not appear to initiate a 
program of de novo cholesterol synthesis, but rather there was a small increase in 
expression of LDLR mRNA after 12 h of efflux conditions. This is in line with 
prostatic epithelial cells preferentially deriving cholesterol from lipoprotein 
endocytosis, rather than the mevalonate pathway (18). This change in gene 
expression does not likely reflect the increase in cholesterol levels that was 
observed by 12 hr because culture conditions where serum free, therefore the 
observed increase may have been from de novo synthesis or a reflection of basal 
differences in cholesterol between the 4 and 12 h groups. Also, mRNA levels of 
SREBP2 and HMGR, both central actors in increasing cellular cholesterol 
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synthesis, are not always indicating of activity and therefore gene expr ssion is a 
limited proxy to determine the response of PC-3 cells to cholesterol efflux.  
 Lipid raft domain cholesterol is a highly concentrated and metabolically 
active depot of cellular cholesterol (36). Diffusion of a number of membrane 
receptors and their adaptor proteins is dependent on the presence of cholesterol 
with these domains and experiments have demonstrated that agents that target raft 
cholesterol compromise membrane signal transduction because of disruption of 
raft integrity (36). Studies examining the molecular dynamics of LXR-ABC1 
mediated cholesterol efflux have demonstrated that raft domain cholesterol is a 
source of membrane cholesterol for efflux to lipid poor apo A-I (18). Therapies 
aimed at targeting raft associated signaling and adaptor protein assembly have 
demonstrated LXR mediated efflux can perturb raft integrity and assembly of raft
adaptor receptors and protein complexes. Therefore a central question is whether 
LXR mediated cholesterol efflux can alter raft cholesterol in PCa cells and 
whether this might attenuate raft associated signaling.  
 Analysis of lipid raft images in PC-3 cells suggests that LXR-ABCA1 
mediated cholesterol efflux does alter membrane raft domains in a pattern similar
to those reported in macrophages. Live cell staining using the raft marker gm-1 is 
a reliable and sensitive tool used by others to demonstrate dynamic changes to raft 
architecture. Co-patching of gm-1 with other raft domains is highly dependant on 
the cholesterol content of these domains (100). Images taken of live cells cultured 
under efflux conditions demonstrated discrete changes to the number of lipid raft 
positive cells. What was interesting was the administration of the LXR ligand 
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alone, in the absence of apo A-I resulted in a slight but non-significant decrease in 
raft positive cells. This effect might have been as a result of a proposed step by
ABCA1, which involves priming the membrane for efflux by re-location of 
cholesterol from raft to non-raft domains. This effect would appear as a decrease 
in raft domain cholesterol content in cells with high expression of ABCA1 
without lipid acceptors. There was also a small but non-significant decreas in raft 
positive cells in apo A-I and vehicle treated cells. This effect was expected, as apo 
A-I will interact ABCA1 protein expressed in unstimulated cells and can initiate 
cholesterol removal (120).  However, it was the combination of the LXR ligand 
T09 and apo A-I which demonstrated the strongest decrease in lipid raft positive 
cells. The decrease in free cellular cholesterol and raft domain positive cells under 
ABCA1, apo A-I dependent cholesterol efflux conditions strongly suggests that 
cholesterol efflux can lead to a decrease in raft domains in PC-3 cells. These data 
suggest that therapies aimed at increasing both LXR activation and circulating 
apo A-I synthesis, could increase the rate of raft domain cholesterol removal and 
negatively impact signal transduction dependant on raft cholesterol content. 











Figure 1. Interactions of T0901317 (T09) with other type 2 Nuclear Receptors 
or Their Targets. LNCaP and PC-3 cells were seeded at a density of 0.5 x 106 
cells/well and grown for 24 h in RPMI 1640 10% FBS and then treated for 48 h 
with either vehicle or 10 µM T09. After treatments cells were subjected to RNA 
isolation and RT-PCR as described in Materials and Methods. mRNA expression 
is expressed as means ± SE of fold change relative to vehicle treated con rol
(dotted line). Bar with an asterisk (*) denotes significant difference compared to 










Figure 2. Comparative expression of LXR, Cholesterol Metabolism Related 
Genes and Cholesterol Levels in LNCaP and PC-3 cells. mRNA levels are 
expressed as means ± SE of comparative fold differences.  Data are representative 
of three independent experiments. A, Relative mRNA levels of LXRα, LXRβ, 
ABCA1, and ABCG1 in LNCaP cells. B, Relative mRNA levels of LXRα, LXRβ, 
ABCA1, and ABCG1 in PC-3 cells. C, Comparative mRNA levels of LXRα, LXRβ 
between LNCaP and PC-3 cells. D, Comparative mRNA levels of ABCA1 and 
ABCG1 between LNCaP and PC-3 cells. PC-3 cell ABCA1 and ABCG1 mRNA 
expression levels were normalized to ABCA1 and ABCG1 mRNA expression in 
LNCaP cells. E, Relative mRNA levels of LXR and Cholesterol Metabolism 
related genes are expressed as fold change relative to LNCaP cells. ns=not 
significant.  F, Cellular cholesterol profile of PC-3 and LNCaP cells. Cells were 
grown for 48 h in 10% FBS followed by lipid extraction and enzymatic 







Figure 3. Concentration-dependent effects of T09, 24,25EC, and 25HC on 
ABCA1 and ABCG1 mRNA expression. LNCaP and PC-3 cells were seeded at a 
density of 0.5 x 106 cells/well and grown for 24 h in RPMI 1640 10% FBS and 
then treated for 24 h with or without 0.1 to 10 µM T09, 24,25EC, or 25HC. After 
treatments cells were subjected to RNA isolation and RT-PCR as described in 
Materials and Methods. Results are expressed as means ± SE of comparative fold 
differences relative to control. Data are representative of three indepe nt 
experiments. Points with an asterisk (*) are significantly different than control    
(p < 0.05). A and B, Dose effects of T09, 24,25EC, and 25HC on ABCA1 and 
ABCG1 mRNA induction in LNCaP cells. C and D, Dose effects of T09, 





Figure 4. Temporal effects of T09, 24,25EC and 25HC on ABCA1 and 
ABCG1 mRNA expression. LNCaP and PC-3 cells were seeded at a density of 
0.5 x 106 cells/well and grown for 24 h in RPMI 1640 10% FBS and then treated 
for 2 to 24 h with or without 5 µM of T09, 24,25EC, or 25HC. After treatments 
cells were subjected to RNA isolation and RT-PCR as described in Materials and 
Methods. ABCA1, ABCG1 mRNA induction is expressed as means ± SE of fold 
change relative to control at each time point. Data are representative of thre 
independent experiments. Points with an asterisk (*) are significantly different 
than control (p < 0.05) A and B, Temporal effects of T09, 24,25EC, and 25HC on 
ABCA1 and ABCG1 mRNA induction in LNCaP cells. C and D, Temporal effects 






Figure 5. Effects of LXRα siRNA on ligand-mediated expression of ABCA1 
and ABCG1 in LNCaP and PC-3 cells. LNCaP and PC-3 cells were transfected 
with or without LXRα siRNA oligonucleotides for 48 h and then treated with or 
without 5 µM of T09, 24,25EC, or 25HC for an additional 48 h. Relative mRNA 
levels are expressed as means ± SE of fold change relative to control. Data are 
representative of three independent experiments. Error bars with a different lett r 
indicate significant differences between groups (p < 0.05). A, Effects of LXRα 
siRNA transfection on basal and ligand inducible LXRα and LXRβ mRNA levels 
in LNCaP cells. B, Effects of LXRα siRNA transfection on basal and ligand 
inducible LXRα and LXRβ mRNA levels in PC-3 cells. C, Effects of LXRα 
siRNA transfection on basal and ligand inducible ABCA1 and ABCG1 mRNA 
levels in LNCaP cells. D, Effects of LXRα siRNA transfection on basal and 




Figure 6. Effects of LXRβ siRNA interference on ligand-mediated expression 
of ABCA1 and ABCG1 in LNCaP and PC-3 cells. LNCaP and PC-3 cells were 
transfected with or without LXRβ siRNA oligonucleotides for 48h and then 
treated with or without 5 µM of T09, 24,25EC, or 25HC for an additional 48h. 
Relative mRNA levels are expressed as means ± SE of fold change relative to 
control. Data are representative of three independent experiments. Error bars with 
a different letter indicate significant differences between groups (p < 0.05). A, 
Effects of LXRβ siRNA transfection on basal and ligand inducible LXRα and 
LXRβ mRNA levels in LNCaP cells. B, Effects of LXRβ siRNA transfection on 
basal and ligand inducible LXRα and LXRβ mRNA levels in PC-3 cells. C, Effects 
of LXRβ siRNA transfection on basal and ligand inducible ABCA1 and ABCG1 
mRNA levels in LNCaP cells. D, Effects of LXRβ siRNA transfection on basal 






Figure 7. Effects of p38, JNK, MAPK and PKA inhibitors on T09 and 25HC 
mediated induction of ABCA1 mRNA. LNCaP and PC-3 cells were pre-treated 
with or without 10 µM kinase inhibitors for p38 (SB203580), JNK (SP600125), 
ERK1/2 (PD98059), or PKA (H89) for 60 minutes followed by treatment with or 
without 5 µM of T09, 24,25EC, or 25HC for 24 h.  Relative ABCA1, ABCG1 
mRNA levels are expressed as means ± SE of fold change relative to control. 
Data are representative of three independent experiments. Error bars with a 
different letter indicate significant differences between groups (p < 0.05). A and 
B, Effects of various kinase inhibitors on ABCA1 and ABCG1 mRNA expression 
in LNCaP cells. C and D, Effects of various kinase inhibitors on ABCA1 and 






Figure 8. Effects of siRNA against p38α/β on T09 mediated induction of 
ABCA1 mRNA. LNCaP cells transfected with either: negative control 
oligonucleotides (-p38) or with 100 nM MAPK14 (+ p38α) and MAPK 11 (+ 
p38β) siRNA oligonucleotides for 48h followed treatment with either vehicle 
(0.05% v/v DMSO) or 1 µM of T09 48 h. After treatments, cells were subjected to 
RNA isolation and RT-PCR as described in Materials and Methods. Relative 
mRNA levels are expressed as means ± SE of fold change relative to vehicle
treated control. Errors bars with an asterisk (***) indicates a significant difference 
between negative control oligonucleotides (-p38α/β) and (+ p38α/β) siRNA 
oligonucleotides. A, Effects of p38α/β siRNA on mRNA expression of p38α and 
p38β in PC-3 cells. B, Effects of p38α/β siRNA on mRNA expression of ABCA1 










Figure 9. Effects of siRNA against PKA on T09 mediated induction of 
ABCA1 mRNA. PC-3 cells were transfected with either: negative control 
oligonucleotides (-PKA siRNA) or with 100 nM PKA siRNA oligonucleotides (+ 
PKA siRNA) for 48 h followed treatment with either vehicle (0.05% v/v DMSO), 
5 µM of T09, or 10 µM of the PKA activator forskolin for 48 h. Relative mRNA 
levels are expressed as means ± SE of fold change relative to vehicle treated 
control. Error bars with an asterisk (*) or a p value indicate significant differences 
between (-PKA siRNA) and or (+ PKA siRNA) where *** = p < 0.001. A, 
Effects of PKA siRNA on mRNA expression of PKA in PC-3 cells. B, Effects of 
PKA siRNA on mRNA expression of LXRα in PC-3 cells. C, Effects of PKA 
siRNA on mRNA expression of LXRβ in PC-3 cells. D, Effects of PKA siRNA on 
mRNA expression of ABCA1 in PC-3 cells. E, Effects of PKA siRNA on mRNA 














Figure 10. LXR mediated Reverse Cholesterol Transport (RCT) in PC-3 
cells. PC-3 cells were loaded with 1µCi/mL of [3H] labeled cholesterol. After 48 h 
PC-3 cells treated with either 1µM of the synthetic LXR ligand T09 or vehicle 
(DMSO 0.05% v/v) for 48 h in serum free, phenol free RPMI-1640 medium. 
After 48 h cells exposed to either vehicle (PBS) or 20 µg/mL of human apo A-I 
for 24 h in serum free medium. Aliquots of culture medium was collected every  
2 h and radioactively determined using a scintillation counter. Data are 
representative of three independent experiments. Error bars with an asterisk (*) 
indicate significant differences between T09 and T09 + apo A-I (p < 0.001). A, 
Temporal changes in cholesterol efflux in PC-3 cells. B, Rate of cholesterol efflux 







Figure 11. Cellular cholesterol levels and gene expression during RTC. PC-3 
cells were seeded under efflux conditions as descried in materials and methods. 
RTC was initiated with 5 and 20 µg/mL of apo A-I in serum free conditions for    
4 h and 12 h.  At 4 and 12 h cellular lipids isolated as described in materials and 
methods. A, Cellular cholesterol levels after 4 and 12h of RTC in serum free 
conditions. Error bars with an asterisk (*) indicate a significant difference 
between T09 and T09 + apo A-I with * = p < 0.05 and *** = p < 0.001). Error 
bars with a cross (†) indicate a significant difference between T09 + apo A-I at  
12 h and T09 + apo A-I at 4 h with ††= p < 0.01.  nd= not detectable. B, PC-3 
cells were treated for 48 h with 1uM T09 in 10% FBS followed by total 
cholesterol analysis. C-G, PC-3 cells were seeded under efflux conditions as 
descried in Materials and Methods. RTC was initiated with 20 µg/mL of apo A-I 
in serum free conditions for 4 h and 12 h.  At 4 h and 12 h total RNA was isolated 
and used for analysis of gene expression. mRNA levels are expressed as means ± 
SE of fold change relative to vehicle treated control. Error bars with an asterisk 
(*) indicate a significant difference between T09 and T09 + apo A-I with ** = p < 
0.01 and *** = p < 0.001). Error bars with a cross (†) indicate a significant 
difference between T09 + apo A-I at 12h and T09 + apo A-I at 4 h with ††= p < 






Figure 12. Effects of LXR mediated on Plasma Membrane Lipid Raft 
Domains. PC-3 cells were plated under conditions of cholesterol efflux as 
described in Materials and Methods and treated with 1 µM of the LXR ligand T09 
for 48 h followed by 4 h of cholesterol efflux initiated with 20 µg/mL apo A-I. 
Following treatments lipid raft domains were labeled with Alexa Fluor conjugated 
cholera-toxin B-subunit (AF-CT-B) and visualized by immunofluorescence 
microscopy. Images captured and analyzed using Nikon NIS elements imaging 
software. Images (40X) A, Micrographs of lipid raft domains in PC-3 cells. B, 




Chapter 3: Isoflavone regulation of ABCA1, ABCG1 mRNA 
levels in Prostate Cancer Cells 
INTRODUCTION 
Experimental Rationale for studies of Isoflavones and Cholesterol 
Metabolism in Prostate Cancer Cells 
 A number of population studies in East Asian males have found a 
correlation between consumption of soy derived foods and a reduced risk for 
developing prostate cancer (PCa) and other maladies (72-77, 79-81).  Isoflavones 
are a class of polyphenols found at high concentrations in soy derived foods and 
are believed to be responsible for their anti-PCa properties (72-77). Studies have 
shown that habitual consumption of soy derived foods results in significantly 
higher concentrations of isoflavones in plasma, urine, and prostatic fluid (76). The 
most commonly found isoflavones found in soya are genistein, daidzein and 
glycitein. Equol, a metabolite of daidzein also found in biological specimens of 
individuals with high soy consumption (74).  
Animal and in vitro studies have identified a number of anti-PCa 
properties of isoflavones including, tyrosine kinase inhibition, modulators of 
androgenic signaling, angiogenesis and apoptosis including inhibition of AR 
signaling (72, 77). Isoflavones can retard the growth of PCa tumors 
experimentally, however doses experimentally administered animals could be 10 
times higher than the equivalent for human consumption (76). Epidemiological 
evidence is inconsistent as to whether these properties of soy or isoflavones result 
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in PCa prevention in individuals with high soy consumption or to healthy men 
without evidence of clinical PCa (76).   
 In addition to the anti-PCa properties of soy isoflavones, these compounds 
have also been reported to posses anti-atherogenic and cholesterol lowering 
abilities (79-81). This includes data demonstrating that consumption of soy and 
soy isoflavones can reduce risk factors for cardiovascular disease including 
lowering low density lipoprotein (LDL) cholesterol levels, increasing high density 
lipoprotein (HDL) cholesterol and increase HDL/LDL cholesterol ratios in 
animals and humans (79-81).  It is still unclear how isoflavones discharge their 
lipid lowering properties. Nevertheless, the cholesterol lowering properties of soy 
isoflavones may provide beneficial to males at risk for PCa, as new data suggest  
that cholesterol is involved in prostate carcinogenesis (61-64). Therefore 
identifying pathways through which isoflavones might affect cholesterol 
metabolism in PCa cells is warranted.  
 In light of the apparent relationship between cholesterol and PCa, this 
study will examined whether isoflavones can modulate the mRNA expression of 
cholesterol reverse cholesterol transporters, ATP-binding cassette, sub-family A, 
member 1, (ABCA1) and sub-family member G 1, (ABCG1) in two cell models 
of PCa, LNCaP and PC-3 cells. ABCA1 and ABCG1 use energy from ATP 
hydrolysis to efflux excess free cellular cholesterol to circulating lipoprotein 
particles such as apo A-I and HDL. Both ABCA1 and ABCG1 come under the 
transcriptional regulation of the nuclear receptor transcription factors live X 
receptors (LXRα, LXRβ), which act to prevent accumulation of excess cellular 
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cholesterol in peripheral tissue. Isoflavones will be tested for their ability to alter 
cholesterol efflux from PCa cells.  
Specific Hypotheses Tested    
Studies will be performed on LNCaP and PC-3 prostate cancer epithelial cells to 
examine the following hypotheses relating to isoflavone and LXR biology: 
a) To test the hypothesis that soy isoflavones can activate mRNA expression 
of LXR responsive genes ABCA1 and ABCG1 in LNCaP and PC-3 cells. 
b) To test the hypothesis that LXRβ and not LXRα will be involved in any 
isoflavone modulation of ABCA1 and ABCG1 mRNA levels.  
c) To test the hypothesis that androgen receptor is involved in isoflavone 
regulation of ABCA1 and ABCG1 mRNA levels in LNCaP cells. 
d) To test the hypothesis that isoflavones can increase the rate of cholesterol 







 Isoflavones are dietary compounds derived from soy foods studied 
extensively for their anti-prostate cancer (PCa) and cholesterol lowering 
properties. Although a strong link between cholesterol and PCa has been reported, 
there has been no examination of whether isoflavones can modulate mRNA 
expression of cholesterol metabolism related genes in prostate carcinoma. This 
study sought to examine whether five isoflavones, genistein, daidzein, equol, 
glycitein and glyceollin could modulate mRNA expression of two LXR 
responsive genes, ATP-binding cassette sub-family members A 1 (ABCA1) and G 
1 (ABCG1) in LNCaP and PC-3 cells. Real time PCR data demonstrated that 
treatment of LNCaP and PC-3 cells with all isoflavones resulted in a one and ten 
fold increase in mRNA expression of ABCA1, ABCG1. In both cell lines, the 
strongest inducers of ABCA1 and ABCG1 mRNA were glyceollin and equol; with 
~8-15 fold mRNA induction of ABCA1, ABCG1 in LNCaP cells respectively and 
~8 fold induction of both ABCA1, ABCG1 mRNA in PC-3 cells.  ABCA1, ABCG1 
mRNA induction in cells treated with genistein, daidzein and glycitein were 
weaker at ~1-3 fold.  Using siRNA for LXR isoforms (LXRα and LXRβ), it was 
also observed that LXRβ is required for isoflavone induction of ABCG1, but not 
ABCA1 in LNCaP cells. mRNA silencing of LXRβ did inhibit isoflavone 
mediated induction of both ABCA1 and ABCG1 mRNA in PC-3 cells. Tritium 
labeled cholesterol efflux assays revealed that a mixture of three glyceollins did 
not increase apo A-I induced cholesterol efflux from PC-3 cells.  
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MATERIALS AND METHODS 
Chemicals and Reagents 
Dharmacon ON-TARGETplus SMARTpool siRNA reagents targeting LXRα 
(NM_005693) (Dharmacon Catalog # L-003413-00), LXRβ (NM_007121) 
(Dharmacon Catalog # L-003412-00) or androgen receptor (AR) (Dharmacon 
Catalog # L-003400-00-0005) were purchased from Thermo Fisher Scientific 
(Lafayette, CO). HiPerFect Transfection Reagent was purchased from Qiagen 
(Santa Clarita, CA).  The synthetic LXR ligand T09 was purchased from Cay an 
Chemical Company, (Ann Arbor, MI). Genistein, daidzein, equol, glycitein and 
human purified apo A-I where purchased from Sigma Chemical Co. (St. Louis, 
MO). [1α,2α (n)-H3] labeled cholesterol was purchased from Perkin Elmer 
(Waltham, MA).  Lipoprotein free serum was purchased from Intracel (Rockville, 
MD). Amplex red cholesterol analysis kit was purchased from Invitrogen 
(Carlsbad, CA). Glyceollins mixture (glyceolins I, II and III) were a gift from Dr. 
Steve Boue (SRRC, ARS, USDA, New Orlean, LA) 
Cell Culture 
The human prostate cancer cell lines LNCaP and PC-3 were purchased 
from the American Type Culture Collection (Manassas, VA) and maintained in 
RPMI-1640 medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen, Carlsbad, CA), 1% glutamine and 100 U/mL 
penicillin and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA) (culture 
medium). Cells were incubated in the presence of 5% carbon dioxide and air at 37 
°C. 
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RNA Isolation and Real-Time Reverse Transcriptase Polymerase Chain 
Reaction (RT- PCR) 
For gene expression experiments, LNCaP and PC-3 cells were seeded in 6 
well plates at a density of  0.5 x 106 cells/well and grown for 24 h in culture 
medium, then treated with various concentrations (0.1-10 µM) of genistein, 
daidzein, equol, glycitein, glyceollin or vehicle (DMSO 0.05% v/v). After 
termination of experiments total RNA was isolated using the TRIzol®  reagent 
(Invitrogen, Carlsbad, CA), and reverse transcribed to complementary DNA 
(cDNA) using StrataScript® First Strand cDNA Synthesis Kit (Stratagene, La 
Jolla, CA) (21). Real time PCR was carried out using a TaqMan Fast Universal 
PCR Master Mix on an ABI 7900HT Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA). The TaqMan probes and primers were purchased 
from Applied Biosystems using inventoried TaqMan gene expression assays: 
LXRα, (assay ID: Hs00172885), LXRβ (assay ID: Hs00173195), ABCA1 (assay 
ID: Hs01059122), ABCG1 (assay ID: Hs00245154), Human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (assay ID: Hs99999905) was used as an 
endogenous control for all gene expression. The following amplification 
parameters were used: 95°C for 20 sec, followed by 40 cycles of amplification at 
95°C for 1 sec and 60°C for 20 sec. Quantitation of mRNA fold changes were 
derived using the ∆ critical threshold (∆Ct) method (22). 
Cell Transfection with Small Interfering RNA (siRNA) 
LNCaP and PC-3 cells were seeded in 6-well plates at a density of 0.2 x 
106 cells/well and grown for 24 h in RPMI-1640 10% fetal bovine serum (FBS) 
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RPMI-1640 containing 1% glutamine and 1% penicillin/streptomycin. After 24 h 
cells were switched to 10% charcoal dextrin treated serum (CDS) media in RPMI-
1640 (without phenol red) containing 1% glutamine and 1% 
penicillin/streptomycin and transfected with 5 nM of Dharmacon ON-
TARGETplus SMARTpool siRNA oligonucleotides targeting LXRα, LXRβ or 
androgen receptor (AR) using the HiPerFect transfection reagent (Qiagen) 
according to the manufactures protocol. Preliminary experiments determined that 
5 nM siRNA oligonucleotides were optimal for 70-80% gene silencing without 
any off target effects. After 48 h of siRNA transfection, cells were switched back 
to 10% FBS and treated with various LXR ligands as described in Materials and 
Methods for an additional 48 h. In experiments involving DHT, LNCaP cells after 
transfection were kept in fresh 10% CDS and treated with 1 nM DHT for   48 h.  
Cholesterol Efflux Assay 
 PC-3 cells were plated in 10% FBS in triplicate and loaded with 1µCi/mL 
of [3H] labeled cholesterol (Perkin Elmer) for 48 h. After 48 h PC-3 cells were 
washed thrice with PBS and switched to serum free conditions (RPMI + 0.2% 
fatty acid free bovine serum albumin (BSA) w/v). Cells were allowed 2 h to 
equilibrate cellular cholesterol in serum free conditions, washed thrice with PBS 
and treated for 48 h with either 1 µM of the LXR ligand T09 or 10 µM glyceollin. 
After 48 h PC-3 cells were washed thrice with PBS + 0.2% BSA and incubated 
with RPMI + 0.2% BSA plus 20 µg/mL of the cholesterol carrier apo A-I to 
initiate cholesterol efflux. Aliquots of 100 µl were collected at multiple time 
points for 24 h, mixed with scintillation liquid and measured for radioactivity on a 
 85
scintillation counter. After 24 h cells were lysed with RIPA buffer (Thermo) and 
protein measured using the bicinchoninic acid (BCA) assay (Thermo) according 
to the manufactures’ protocol. Efflux of vehicle treated cells will be subtracted 
from efflux of all groups as background and efflux will be expressed as CPM of 
radioactivity in the cell culture medium per mg of cellular protein. Mean 
differences in efflux between isoflavone or T09 + apo A-I and apo A-I alone will 
be measured at time points within the linear range of efflux.  
Statistics 
 Statistical analysis of data was carried out with the GraphPad PRISM4 
program (GraphPad Software, Inc.). Contrasts of group means will be computed 
using one or two factor ANOVA followed by Bonferroni post hoc tests. The 
unpaired Student's t test will be used to compare experiments between two 
groups. Gene expression results will be expressed as means ± SE of comparative 
fold differences. Mean differences of post-hoc analyses are considered significant 
when p value is < 0.05.  
RESULTS 
Concentration Effect of Soy Isoflavones on ABCG1 and ABCA1 mRNA 
Expression  
To measure the concentration effects of soy isoflavones on mRNA 
expression of ABCA1 and ABCG1, LNCaP and PC-3 cells were treated with 
increasing concentrations (0.1-10 µM) of genistein, daidzein, equol, glycitein or 
glyceollin for 48 h. In both LNCaP (Fig. 1A) and PC-3 cells (Fig. 1C), all 
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isoflavones resulted in a dose response in ABCA1 mRNA expression. Except for 
glycitein, all isoflavones resulted in a dose dependant increase in ABCG1 mRNA 
in both cell lines (Fig. 1B and 1D). LNCaP cells treated with various 
concentrations of glyceollin resulted in a ~2-15 fold induction of ABCA1 mRNA 
compared to a ~2-8 fold induction equol treated cells (Fig. 1A). Whereas, the 
magnitude of genistein’s, daidzein’s and glycitein’s effect on ABCA1 mRNA 
expression in LNCaP cells was similar for each at ~0.5-3 fold increase (Fig. 1A). 
Glyceollin treatment resulted in a ~2-16 fold induction of ABCG1 mRNA in 
LNCaP cells, compared to a ~2-4 fold induction by equol and a ~1-2 fold 
induction by genistein, daidzein and glycitein (Fig. 1B).  
Glyceollin and equol resulted in ~2-8 and ~2-6 fold increase in ABCA1 
mRNA expression respectively in PC-3 cells (Fig. 1C), where the effect of 
genistein, daidzein and glycitein on ABCA1 mRNA induction was ~1-2 fold (Fig. 
1C).   In a similar pattern to LNCaP cells, glyceollin and equol treatments in PC-3 
cells resulted in a ~2-7 and ~2-4 fold increase in ABCG1 mRNA expression (Fig. 
1D), however treatments with genistein, daidzein caused an ~1-2 fold change, 
while glycitein had no effect on ABCG1 mRNA expression in PC-3 cells (Fig. 
1D).  
Temporal Effect of Soy Isoflavones on ABCG1 and ABCA1 mRNA 
Expression 
Temporal changes in ABCA1 and ABCG1 mRNA expression in LNCaP 
and PC-3 cells treated with 5 µM of genistein, daidzein, equol, glycitein or 
glyceollin for 8-72 h was also determined. Fig. 2A and B shows that glyceollin 
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treatment in LNCaP cells lead to a significant increase in ABCA1 and ABCG1 
mRNA at 8 h compared to cells treated with genistein, daidzein, equol, or 
glycitein (~2-3 fold vs. ~0 fold). The same effect in glyceollin treated PC-3 cells 
was also observed, with relative ABCA1, ABCG1 mRNA levels increasing 
approximately 2 fold at 8 h with little or no fold changes in cells treated with all 
other isoflavones (Fig. 2C and D).  In daidzein and equol treated LNCaP and PC-
3 cells, relative ABCA1 mRNA levels significantly increased after 48 h (Fig. 2A 
and C).  LNCaP cells treated with genistein showed significant relative ABCA1 
mRNA changes at 24 h, where genistein’s effect on ABCA1 mRNA in PC-3 cells 
was apparent only at 72 h (Fig. 2A and C).  Glycitein treatment in LNCaP and 
PC-3 cells had no significant effect on ABCA1 mRNA levels at any time point 
(Fig. 2A and C).  In contrast glyceollin treated LNCaP and PC-3 cells; a 
significant increase in relative ABCA1, ABCG1 mRNA levels at all time points 
was observed (Fig. 2A-D).  At 48 and 72 h equol treated LNCaP and PC-3 cells 
showed ~3 and ~2 fold changes in relative ABCG1 mRNA respectively (Fig. 2B 
and D).  Relative ABCG1 mRNA levels in PC-3 cells treated with genistein, 
daidzein and glycitein showed no increases at any time point, where LNCaP cells 
treated with the same isoflavones showed significant increases in relative ABCG1 
mRNA levels at 48 and 72 h (Fig. 2B and D).  
LXRβ Involvement in Isoflavones Regulation of ABCA1 and ABCG1 mRNA 
Expression Varies between Cell Types  
Transfection of LNCaP cells with siRNA against LXRβ or LXRα could 
not inhibit isoflavone mediated increase in ABCA1 mRNA levels (Fig 3B and D).  
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A significant increase in ABCA1 mRNA levels was observed in glyceollin treated 
cells with siRNA against LXRβ (Fig 3D).  siRNA against LXRβ did significantly 
inhibit isoflavone mediated induction of ABCG1 mRNA levels in LNCaP cells, 
while siRNA against LXRα had no effect (Fig 3B and D). In PC-3 cells, both 
ABCA1 and ABCG1 mRNA induction by all isoflavones was inhibited in cells 
transfected with LXRβ siRNA (Fig. 4B and D); while LXRα siRNA had no effect 
on either ABCA1 or ABCG1 mRNA induction by any isoflavones (Fig. 4D).  
Involvement of Androgen Receptor in Isoflavone Regulation of ABCA1 and 
ABCG1 mRNA Levels in LNCaP cells.  
 It has been reported and confirmed by this laboratory that androgens can 
oppose the mRNA expression of ABCA1 in LNCaP cells (102). The antagonism 
of ABCA1 mRNA by androgen in LNCaP cells may provide a new mechanism 
that can be tested in isoflavone regulation of ABCA1. The lack LXRα or LXRβ 
involvement in isoflavone regulation of ABCA1 mRNA in LNCaP cells suggests 
an alternative pathway is involved. Work in this laboratory has demonstrated that 
some isoflavones such as genistein, equol and glyceollin can oppose the 
transcriptional program of AR (77, 121); therefore it was tested whether 
isoflavone regulation of ABCA1 mRNA requires the presence of AR in LNCaP 
cells. To test this LNCaP cells were transfected with either 5 nM siRNA against 
AR or vehicle negative control for 48 h, followed by treatment with 5 µM 
isoflavones for an additional 48 h.  
 Transfection with AR siRNA lead to an increase in basal ABCA1 mRNA 
levels, but this effect was not significant (Fig 5). AR siRNA significantly opposed 
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ABCA1 mRNA induction by glyceollin and glycitein (p < 0.001 and p < 0.05) 
respectively. There was no significant effect by AR siRNA on ABCA1 mRNA 
levels in genistein, daidzein and equol treated LNCaP cells.  AR siRNA 
significantly inhibited ABCG1 mRNA induction by equol and glyceollin, (p < 
0.001). AR siRNA lead to a significant increase in basal mRNA levels of ABCG1 
in control cells, (p < 0.05). These data suggest that the steroid hormone pathway, 
through AR, is involved in glyceollin and glycitein modulation of ABCA1 mRNA 
and equol and glyceollin regulation of ABCG1 mRNA levels in LNCaP cells, 
where the regulation of these targets in PC-3 cells appears to be exclusively 
through LXRβ.  
Cholesterol Efflux from PC-3 cells  
 To evaluate whether isoflavone mediated increase in ABCA1 mRNA 
levels can results in increased reverse cholesterol transport from transformed 
epithelial cells, PC-3 cells loaded with tritium labeled cholesterol werepre-treated 
with either vehicle, 1 µM  T09 or 10 µM of glyceollin for 48 h and then 
stimulated to begin cholesterol efflux with lipid poor, human apo A-I. Cholesterol 
efflux was determined at multiple time points as described in Materials and 
Methods.  Pre-treatment with the synthetic LXR ligand T09 resulted in significa t 
increase apoA-I mediated cholesterol efflux compared to vehicle treated control 
(Fig 6)  During initial experiments glyceollin significantly increased cholesterol 
efflux from PC-3 cells, however this was not specific as it occurred with and 
without the presence of the lipid carrier apo A-I. Further experiments showed no 
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effect of glyceollin on increased cholesterol efflux with the mean cholesterol rate 
of three independent experiments showing no effect in cholesterol efflux (Fig 6).   
DISCUSSION 
 There is interest in identifying compounds from the diet which could 
protect against the onset of prostate and other cancers. These compounds, labeled 
as “bioactives” phytochemicals are believed to be responsible for health 
promoting associations, lower cancer risk, decreased heart disease associated with 
certain foods or dietary patterns. With the current interest in LXR as a putative 
anti-PCa target in models organism and cells, this arm of the study sought to 
examine whether a number of isoflavones studied for their anti-PCa and lipid 
lowering properties can active the LXR-ABCA1 pathway and cholesterol efflux 
in PCa cells.  
Soy Isoflavones increase mRNA levels of ABCA1 and ABCG1 in LNCaP and 
PC-3 cells.  
 Isoflavones were first characterized for their potential estrogenic activity 
due to their structural similarity to estradiol (122). There is a body of data 
demonstrating that women have a lower risk of cardiovascular disease until they 
reach menopause, therefore research examining estrogen and estrogenic 
compounds as lipid lowering agents grew (122). Studies examining lipid lowering 
effects of soy, soy protein isolate or soy isoflavones has produced mixed results. 
The lack of consistent effect of soy or it’s derivatives on lipid metabolism lead to 
the FDA  in 2008 to retract a health claim suggesting that 25 g of soy intake per 
day can reduce the risk of cardiovascular disease (80). The new claim, suggests 
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that soy or its derivatives, soy protein or isoflavones have only a modest effect at 
best on lowering serum cholesterol levels and attenuating risk for cardio vascular 
disease. However, it is possible that soy or soy isoflavones could have 
unmeasured effects on tissue lipid metabolism which may not be reflected by 
serum cholesterol or triglyceride profile. Therefore tissue or cell type examination 
of the effects of isoflavones may reveal biological properties on targets involved 
in lipid metabolism. The effects of isoflavones such as genistein and daidzein on 
activation of estrogen receptors have been well established (72), but less is known 
about promiscuous activation of other nuclear receptors such as PPARs, LXR and 
FXR in liver or other metabolically active tissue. Ricketts et al. demonstrated that 
the isoflavones genistein, daidzein and glycitein all activated LXR reporter 
vectors in HepG2 cells as strongly as the endogenous LXR ligand 22(R) 
hydroxycholesterol (82). In the current study we examined whether isoflavones 
could increase mRNA levels of LXR responsive genes ABCA1 and ABCG1. Real 
time PCR data demonstrated that all the isoflavones tested in this study resulted in 
an increase in mRNA levels of ABCA1 and ABCG1 in both LNCaP and PC-3 
cells. The effect of isoflavones on expression of ABCA1 and ABCG1 was dose 
dependant and, for glyceollin, the most robust inducer of these genes, lead to a 
significant increase in less than 24 h.  
LXRβ is required for isoflavone regulation of ABCA1 and ABCG1. 
 In a pattern that mirrored those observed in the synthetic LXR ligand 
study, siRNA transfection studies revealed that isoflavones require LXRβ in 
mediating their induction of ABCA1 and ABCG1 mRNA, but there were some 
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exceptions with neither LXRα nor LXRβ appearing to be involved in isoflavone 
regulation of ABCA1 in LNCaP cells. The apparent lack of involvement of LXRs 
in isoflavone regulation of ABCA1 mRNA levels suggests a either non-genomic 
regulation of ABCA1 or activation of other nuclear receptors. Pharmacological 
inhibitor studies revealed the PKA inhibitor H89 might be involved in genistein 
regulation of ABCA1, however these findings studies were inconclusive and 
yielded data which was non-reproducible.  
Androgen Receptor involvement in Isoflavone Regulation of ABCA1 and 
ABCG1. 
 This study also examined whether isoflavones may influence expression 
of ABCA1 and ABCG1 by blocking the AR antagonism on LXR responsive 
genes ABCA1 and ABCG1. Transfection of the hormone responsive LNCaP cells 
with siRNA against AR did significantly opposed glycitein and glyceollin 
induction of ABCA1 mRNA levels (Fig 5B) and equol and glyceollin induction of 
ABCG1 mRNA levels (Fig 5C). It was interesting to observe that silencing of AR 
lead to a decrease in isoflavone induction of ABCA1 and ABCG1, because of the 
clear increase that occurred in basal levels of these genes when cells where 
transfected with AR siRNA. This data may suggest lack of AR also leads to 
changes to ill-defined pathways which isoflavone interact with to increase basal 
ABCA1/G1 mRNA levels. Nevertheless, because of the interest in isoflavones as 
modulators of the sex steroid hormone axis, these data present a novel pathway to 
interrogate in understanding the biological interactions between isoflavones and 
PCa hormone signaling.  
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Glyceollin failed to increase LXR-ABCA1 mediated Cholesterol Efflux 
 As the most robust activator of ABCA1 and ABCG1 mRNA levels in both 
LNCaP and PC-3 cells, glyceollin was used to examine isoflavone effects on 
cholesterol efflux in PC-3 cells. This study was essential to examine whether the 
observed upregulation of ABCA1, ABCG1 mRNA expression extended to 
functional changes to cellular cholesterol efflux. Despite some experimental 
evidence that treatment of PC-3 cells with glyceollin increased apo A-I mediated 
cholesterol efflux, there was not consistent evidence of this with the aggregate of 
data revealing no effect. This was not expected, as previous gene expression and 
cholesterol efflux with the synthetic LXR ligand showed parity between increases 
in ABCA/ABCG1 mRNA levels and cholesterol efflux. However, the post-
translational regulation and stability of ABCA1 protein levels involves a number 
of adaptor proteins including PKA phosphorylation of ABCA1 at a number of 
serine residues which help maintain ABCA1 levels during cholesterol efflux. In 
the current study neither ABCA1 stability nor protein levels where assessed and 
therefore cannot make judgment about the effects of isoflavones on protein levels 
of ABCA1, therefore it warranted to conduct further studies of ABCA1 protein 
stability and or phosphorylation status under the influence of isoflavones. Based 
on the structural requirements for ligands of LXRs, it is highly unlikely that 
isoflavones are direct activators of LXRs and therefore the increased expression 
of ABCA1 and ABCG1 mRNA might involve an indirect effect mechanism. 
However there is no evidence based on mRNA expression that isoflavones 
indirectly increase basal levels of either LXR isoform. Nevertheless, it does not 
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appear that isoflavones can act as modulators of LXR mediated cholesterol efflux 
in PC-3 cells. Despite the evidence that isoflavones might possess lipid lowering 
effect, the current study does not demonstrate this extends to functional changes 


















List of Figures with legends 
 
Figure 1. Concentration-dependent effects of Isoflavones on ABCA1 and 
ABCG1 mRNA expression. LNCaP and PC-3 cells were treated for 48 h with or 
without 0.1 to 10 µM genistein, daidzein, equol, glycitein or glyceollin. A and B, 
Dose effects of isoflavones ABCA1 and ABCG1 mRNA induction in LNCaP cells. 
ABCA1, ABCG1 mRNA induction is expressed as means ± SE of fold change 
relative to control. Data are representative of three independent experiments. 
Points with an asterisk (*) are significantly different than control (p < 0.05). C 
and D, Dose effects of isoflavones on ABCA1 and ABCG1 mRNA induction in 








Figure 2. Temporal effects of Isoflavones on ABCA1 and ABCG1 mRNA 
expression. LNCaP and PC-3 cells treated for 2 to 24 h with or without 5 µM of 
genistein, daidzein, equol, glycitein or glyceollin. After treatments cellwere 
subjected to RNA isolation and RT-PCR as described in materials and methods. A 
and B, Temporal effect of isoflavones on ABCA1 and ABCG1 mRNA induction 
in LNCaP cells. ABCA1, ABCG1 mRNA induction is expressed as means ± SE of 
fold change relative to control at each time point. Points with an asterisk (*) are 
significantly different than control (p < 0.05). C and D, Temporal effect of 
isoflavones on ABCA1 and ABCG1 mRNA induction in PC-3 cells. ABCA1, 
ABCG1 mRNA induction is expressed as means ± SE of fold change relative to 
control at each time point. Points with an asterisk (*) are significantly different 





Figure 3. Effects of LXRα siRNA on isoflavone mediated expression of 
ABCA1 and ABCG1 in LNCaP cells. LNCaP cells were transfected with or 
without LXRα siRNA oligonucleotides for 48 h and then treated with or without 5 
µM genistein, daidzein, equol, glycitein or glyceollin for an additional 48 h. 
Relative mRNA levels are expressed as means ± SE of fold change relative to 
control. Error bars with a different letter indicate significant differences between 
groups (p < 0.05). A, Effects of LXRα siRNA transfection and isoflavones on 
LXRα, and LXRβ mRNA levels in LNCaP cells. B, Effects of LXRα siRNA 
transfection and isoflavones on ABCA1 and ABCG1 mRNA levels in LNCaP 
cells. C, Effects of LXRβ siRNA transfection and isoflavones on ABCA1 and 
ABCG1 mRNA levels in LNCaP cells. D, Effects of LXRβ siRNA transfection 








Figure 4. Effects of LXRα siRNA on isoflavone mediated expression of 
ABCA1 and ABCG1 in PC-3 cells. PC-3 cells were transfected with or without 
LXRα siRNA oligonucleotides for 48 h and then treated with or without 5 µM 
genistein, daidzein, equol, glycitein or glyceollin for an additional 48 h. Relative 
mRNA levels are expressed as means ± SE of fold change relative to control. 
Error bars with a different letter indicate significant differences b tween groups (p 
< 0.05). A, Effects of LXRα siRNA transfection and isoflavones on LXRα, and 
LXRβ mRNA levels in PC-3 cells. B, Effects of LXRα siRNA transfection and 
isoflavones on ABCA1 and ABCG1 mRNA levels in PC-3 cells. C, Effects of 
LXRβ siRNA transfection and isoflavones on ABCA1 and ABCG1 mRNA levels 
in PC-3 cells. D, Effects of LXRβ siRNA transfection and isoflavones on ABCA1 












Figure 5. Effects of AR siRNA on isoflavone mediated expression of ABCA1 
and ABCG1 in LNCaP cells. LNCaP cells were transfected with or without AR 
siRNA oligonucleotides for 48 h and then treated with or without 5 µM genistein, 
daidzein, equol, glycitein or glyceollin for an additional 48 h. Relative mRNA 
levels are expressed as means ± SE of fold change relative to control. Error bars 
with an asterisk indicate a significant difference between –AR transfected and 
+AR siRNA transfected cells with *=p < 0.05, **= p < 0.01 and ***= p < 0.001. 
A, Effects of AR siRNA on AR mRNA levels in LNCaP cells. B, Effects of AR 
siRNA transfection and isoflavones on ABCA1 and ABCG1 mRNA levels in 
LNCaP cells. C, Effects of AR siRNA transfection and isoflavones on ABCG1 











Figure 6. Effects of Glyceollin on apo A-I mediated Reverse Cholesterol 
Transport. PC-3 cells were loaded with 1µCi/mL of [3H] labeled cholesterol. 
After 48 h PC-3 treated with either 1µM of the synthetic LXR ligand T09, vehicle 
(DMSO 0.05% v/v), or 10 µM glyceollin for 48 h in serum free, phenol free 
RPMI-1640 medium. After 48 h cells were exposed to either vehicle or 20 µg/mL 
of human apo A-I for 24 h in serum free medium to initiate RCT. Aliquots of 
culture medium was collected every 2 h and radioactively determined using a 
scintillation. Data are representative of the mean ± SE of three indepent 
experiments. Error bars with an asterisk (*) indicate significant differences 
between apo A-I and T09 + apo A-I (p < 0.01).  A, Temporal changes in 






Chapter 4: The Pro-Biotic, Lactobacillus casei, Prevents 
Cholesteryl-ester Accumulation and LPS modulation of the 
LXR and Inflammatory Axis in Alveolar Macrophages from 
Ossabaw pigs fed a High Fat Diet.  
INTRODUCTION 
Experimental Rationale 
 It is now well documented that obesity and hypercholesterolemia can 
promote a pro-inflammatory state and contribute to inflammation related 
morbidities such as atherosclerosis, stroke and cardiovascular disease (52). There 
is recent data demonstrating that obesity and hypercholesterolemia can also lead 
to altered pulmonary immunity (53-55). Alveolar macrophages have a 
fundamental role in pulmonary innate immunity through their ability to recognize 
and phagocytose pathogenic organisms and to orchestrate and expand the adaptive 
immune response through secretion of inflammatory mediators and antigen 
presentation (50). As coordinators of immune surveillance and pulmonary 
function, AM may contribute to altered pulmonary phenotype associated with 
obesity and hypercholesterolemia.  
 High fat, obesogenic diets increase adiposity and elevate serum cholesterol 
levels. Through a number of proposed mechanism discussed in more detail in 
citation (123, 124), it is has been demonstrated that serum low density lipoprotein 
cholesterol (LDL) can cross the sub-endothelial space of arterial sites where it is 
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prone to oxidation and is readily internalized by macrophages via a number of 
scavenger receptors (123,124). Macrophage endogenous cellular cholesterol 
metabolism is balanced between uptake (via LDL receptors and scavenger 
receptors) and efflux via LXR-ABCA1 (18). However, it has been demonstrated 
that feedback inhibition of scavenger receptors such as CD36 is impaired by 
phagocytosis of modified LDL cholesterol, potentially disrupting the balance of 
cholesterol removal and promoting cholesterol retention by macrophages (124). 
LXRs exist to protect macrophages and other cells from unchecked accumulation 
of cholesterol thought its ability to induce cholesterol efflux to lipid poor 
lipoproteins (18). However, if the micro-environmental conditions favor 
macrophage cholesterol retention due to either compromised efflux or increased 
uptake of modified cholesterol, accumulation of cholesteryl-ester rich cytoplasmic 
lipid droplets occurs and leads to onset on a macrophage foam cell development 
(123, 124). Continued accumulation of lipids will eventually lead to macrophage 
foam cell apoptosis and release of their internalized lipids and inflammatory 
mediators. There is a large body of data detailing an altered immunocompetency 
of peritoneal or atheroma derived foam cells macrophages against Chlamydia 
pneumoniae infection (125-127). However, in lungs, clinical detection of alveolar 
lipid laden macrophages is associated with poor pulmonary host defense and 
pulmonary function (128).   
 Experimental studies have led to the belief that hypercholesterolemia can 
overwhelm LXR regulation of cholesterol metabolism and the immune response 
and negatively impact both pathways (24). This may have overarching 
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consequences in tissue such as the lungs where lipid accumulation and 
inflammation can alter organ function and promote disease (51-54). Numerous 
studies link bacterial infection with the onset of foam cell macrophage phenotype 
(125-127). Pathogens can oppose LXR mediated cholesterol efflux in 
macrophages through activation of TLR4 and TLR2 downstream effectors 
MyD88 and IRF-3 and promote onset of a lipid laden foam cell phenotype (24, 
128, and 130). Administration of LXR ligands can oppose this mechanism 
through direct antagonism of IRF-3 and by increases removal of excess free 
cholesterol (129, 130). This is the basis for intensive scrutiny of LXR as 
atheroprotective target in treatment of cardiovascular disease.  In pulmonary 
macrophages it is less clear what role LXRs can have in attenuating either 
bacterial or diet induced onset of a foam cell phenotype. Studies have 
demonstrated that disruption of ABCA1 or ABCG1 mediated efflux from 
pulmonary AM leads impaired pulmonary function and leads to an augmented 
release of pro-inflammatory mediators such as IL-1β, TNF-α, IL-6 and IL-8 in 
response to bacterial endotoxin lipopolysacharide (LPS) (51-54).   
 Because AM macrophages contribute significantly to pulmonary 
inflammation, they represent an important target of therapies aimed at preventing 
or diminishing lipid and inflammation related pathologies.  In recent years, a 
growing body of evidence has suggested that increased presence of some 
intestinal probiotic bacteria is associated with a decreased risk for inflammatory 
related conditions in the lungs such as asthma (131). Pro-biotics are host or 
commensal-derived bacteria such as L ctobacillus reuteri, Lactobacillus casei, 
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and Bifidobacterium longum, which can form bio-films in the lower intestinal 
tract of their host (132-134).  Pro-biotic bacteria are defined by the World Health 
Organization as “any live microorganism which, when administered in adequate 
amounts, confer a health benefit on the host” (134).  The basis for this definition 
comes from a body of data demonstrating that accumulation of these probiotic 
bacteria by diet can beneficially regulate host immunity in the gastrointesti al 
tract and in peripheral tissue (132-134). Clinical studies have demonstrated that 
daily supplementation with some probiotic species can increase gene expression 
of regulatory cytokines such as IL-10 and TGF-β and oppose expression pro-
inflammatory cytokines such as TNF-α and IL-12 in the lamina propria of patients 
with irritable bowel syndrome, Crohn’s’ disease and ulcerative colitis as 
effectively as corticosteroids (132, 133). Supplementation with some strains of 
probiotic bacteria has also been shown to decreases the magnitude of pulmonary 
inflammation in patients with cystic fibrosis and lower serum cholesterol 
lipoprotein levels (132, 133). However, this effect is strain specific as some 
probiotic bacteria strains can actually increase systemic expression of 
proinflammatory mediators such as IL-6 and TNF-α (135). The observed 
disparities between some probiotic strains to benefits to host biology confounds 
broad advocacy for use of these bacteria to ameliorate inflammatory or lipid 
related maladies. Nevertheless, the evidence that some probiotic bacteria can 
positively affect inflammatory conditions outside of those observed in the gut and 
to lower serum cholesterol levels, warrants examination of each specifies to 
determine the presence of unique biological properties.  Furthermore, the potential 
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for some probiotic bacteria to positively affect inflammation conditions and lower 
serum cholesterol levels make it an ideal therapy to test against conditions where 
both dyslipidemia and inflammation are involved.  
 This study will examine whether alveolar macrophages (AM) from 
juvenile Ossabaw pigs fed a HF diet undergo foam cell formation and exhibit and 
exaggerated immune response to LPS stimulation ex vivo. HF diets will also be 
examined for any interactions with the LXR mediated pathways in light of the 
central role that LXRs play in macrophage cholesterol metabolism (24). This 
study will also examine whether daily supplementation with the probiotic 
Lactobacillus casei can oppose any of the pro-inflammatory or lipid altering 
effects of a HF diet. It will also be examined whether LXR activation ex-vivo can 
oppose the inflammatory effect of LPS and whether this affect may interact with 
either PB or HF diets.  
Specific Hypotheses Tested: 
a) To test the hypothesis that an obesogenic, high fat (HF) diet or a HF diet 
supplemented with the probiotic Lactobacillus casei (HFPB) can modulate 
cholesteryl-ester accumulation and the LXR dependant pathway in alveolar 
macrophages (AM) isolated from juvenile Ossabaw pigs.  
b) To test the hypothesis that HF feeding leads to an exaggerated immune 
response in AM stimulated by LPS ex vivo.  
c) To test the hypothesis that LPS stimulation ex vivo can oppose LXR 
transcriptional activation in AM.  
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d) To test the hypothesis that AM from HFPB fed pigs will have decreased gene 
and protein expression of inflammatory mediators compared to HF fed pigs.  
e) To test the hypothesis that LXR activation ex-vivo is anti-inflammatory. 
ABSTRACT 
 Liver X Receptors (LXRs) are important regulators of cholesterol 
metabolism and the inflammatory response in macrophages. It is hypothesized 
that hypercholesterolemia can lead to impaired cholesterol metabolism by LXRs 
leading to macrophage cholesteryl-ester (CE) accumulation and an altered 
inflammatory response. High fat (HF) diets can lead to dyslipidemia and promote 
a pro-inflammatory phenotype marked by alterations of macrophage function and 
increased expression of pro-inflammatory mediators. As modulators of 
inflammation and cholesterol metabolism LXRs might prevent or diminish 
dyslipidemia and inflammation related pathologies caused by HF diets.  Certain 
probiotic bacteria also have anti-inflammatory properties but have not been test d 
for any interactions with the LXR pathway in macrophages. The present study 
sought to determine whether dietary supplementation with the probiotics bacteria 
Lactobacillus casei (L.casei) to Ossabaw pigs would oppose the pro-inflammatory 
effects of a HF diet on expression of genes related to cholesterol metabolism and 
the pulmonary innate immune response in isolated alveolar macrophages (AM).  
AM isolated from pigs fed an HF diet had significantly higher concentrations of 
CE compared with AM from control (C) diet fed pigs suggesting the formation of 
a foam cell phenotype. AM from pigs fed HF diet supplemented with L. casei 
(HFPB) had no significant accumulation of CE. We observed that AM from pigs 
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fed a control (C) diet supplemented with L. casei (CPB), had significantly higher 
mRNA levels of IL-8 and IL-6 in response to LPS. Protein analysis cell culture 
supernatants revealed that AM from HFPB fed pigs had significantly lower LPS 
mediated protein expression of IL-1β than AM from HF fed pigs.  Ex-vivo 
activation of LXR with a specific LXR ligand T0901317 (T09) significantly 
opposed LPS mediated upregulation of IL-1β, IL-6, IL-8 and IL-10 mRNA levels 
in AM from HF, HFPB and CPB fed pigs. However, T09 only opposed LPS 
mediated protein expression of IL-1β in AM from HF fed pigs. Finally, it was 
observed that LPS stimulation lead to significant inhibition of LXR transcription 
of LXRα, ABCA1, ABCG1, cholesterol 25 hydroxylase (CH25H) and PPARγ in 
AM. This effect was abrogated by L. casei for ABCA1, CH25H and PPARγ 
mRNA expression. This study demonstrates that a HF, obesogenic diet 
supplemented with the probiotic L. casei can prevent CE accumulation in 
pulmonary AM and dampen LPS mediated stimulation of IL-1β and TNF-α. 
Moreover, dietary supplementation with L. casei opposed LPS antagonism of the 
LXR and cholesterol metabolism related genes: ABCA1, CH25H and PPARγ. 
Taken together these data demonstrate a new role for L. casei in modulating 
pulmonary inflammation and cholesterol metabolism.  
MATERIALS AND METHODS 
Animals and Diets 
 Twenty, 7 week old female Ossabaw pigs were obtained from Indiana 
University Ossabaw production facility.  Upon arrival pigs were housed in barn 
stalls with a nonabsorptive concrete floor surface, with one pig per pen until 
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adjustment to new surrounds. After adjustment, two pigs were placed in each pen 
and had access to water ad libitum and feed was measured daily. Animals (n=20) 
were randomly assigned to receive one of the following diets: i) control (n=10), 
(C) diet at 2900 cal/ kg body weight per day [13% kcal fat, 22% kcal protein and 
64% kcal carbohydrate] or ii), a high fat (n=10), (HF) diet at 3500 cal/kg body 
weight per day [33% kcal fat, 17% kcal protein, 48% kcal carbohydrate]. Within 
the C and HF diet groups,  animals (n=5) where further randomized to receive 
either a daily oral gavage of either 1 x 1010 colony forming units (cfu) of the 
probiotic Lactobacillus casei (admixed in maltrodextin) or vehicle placebo 
(maltrodextin alone) . These dietary groups were further categorized as either: iii) 
control diet + probiotic (CPB), or iv) a HF diet + probiotic (HFPB). Animals were 
maintained on each of the four diets for 28 weeks until study end.  
Pulmonary Bronchial Alveolar Lavage 
 Alveolar macrophages (AM) were isolated from pigs at necropsy by 
bronchial alveolar lavage (BAL) as previously described (136).  Briefly, the right 
lobe of a lung was gravity filled with 500 ml of PBS, followed by massaging for 
30 s and draining of the cell suspension into 50 ml polypropylene tubes. The cells 
were washed in PBS and resuspended in RPMI 1640 medium and used for ex-vivo 
experiments the same day.  
Unstimulated AM and Ex-vivo AM Experiments 
 Cell counts and viability of AM isolated from BAL were determined using 
trypan blue staining and hemocytometer counting. Determination of a diet effect 
on AM gene expression, 1 x 107 cells were counted from freshly isolated BAL 
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fluid and immediately frozen at -80 °C without serum for future gene expression 
analysis. For ex vivo experiments,  AM from each animal were resuspended in 
macrophage culture medium [RPMI 1640, 10% FBS, 1% non-essential amino 
acids, 1% sodium pyruvate,  10 mM HEPES, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 1.5 g/L sodium bicarbonate] and seeded at a density of 2.5 x 106 
cells/mL in 6 well plates. AM from each animal were treated with either: vehicle 
(0.125% DMSO), 0.5 ng/mL lipopolysaccharide (LPS), 2.5 µM of the synthetic 
LXR ligand T09 or LPS + T09 for 24 h. After 24 h, cell culture supernatants were 
collected and frozen for subsequent protein analysis and cells where lysed with 2
mL of TRIzol® reagent (Invitrogen, Life Technologies, Carlsbad, CA), and frozen 
for subsequent RNA isolation and gene expression analysis.  
Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT- PCR) 
Total RNA from unstimulated and ex vivo AM cell lysates was isolated 
using the PureLink® RNA isolation kit (Invitrogen, Life Technologies, Carlsbad, 
CA) according to the manufacture’s protocol. Integrity and concentration of 
purified RNA were determined using Experion™ RNA gel electrophoresis 
analysis chips (Bio-Rad, Hercules, CA).  Sample RNA integrity was compared to 
an intact RNA standard and scored using a validated RNA quality indicator (RQI) 
assigned by the Experion RNA analyzer software, version 3.2.  All the samples 
scored between 9.6 and 10, with a score of 10 indicating no RNA degradation. 
First-strand cDNA synthesis was made from 1  µg of total RNA using 
Superscript™ III reverse transcriptase according to the manufacturer's p otocol 
(Invitrogen, Life Technologies, Carlsbad, CA). Real-time RT-PCR was used for 
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amplification of panel of genes related to inflammation and lipid metabolism 
listed in Table 1.  All probes and primers for real-time RT-PCR were previously 
designed using the Primer Express (Applied Biosystems, Foster City, CA, USA) 
software package and nucleotide sequences obtained from GenBank or the TIGR 
porcine EST database.  A list of the sequences used for primer design are 
available online at the USDA Porcine Immunology and Nutrition (PIN) database:  
www.ars.usda.gov/Services/docs.htm?docid=6065. Real-time RT-PCR was 
performed using a 25 ng of cDNA template (cDNA concentrations are based on 
RNA concentrations determined from gel electrophoresis and assume 100% 
conversion of total RNA to first strand cDNA) and 25 µl of Absolute™ QPCR 
low ROX master mix (ABgene, Epsom, UK) per sample on an ABI PRISM 7500 
sequence detection system (Applied Biosystems, Foster City, CA).  Quantitatio  
of mRNA fold changes was derived using the delta threshold cycle (∆ Ct) 
method. Data are presented as the mean fold change in gene expression relevant 
to either C fed animals or vehicle treated controls.  
Macrophage Cholesterol Analysis 
 On the day of necropsy, 1 x 108  cells of AM were aliquoted and frozen at  
-80o C for future analysis of cellular cholesterol levels. On the day of analysis, 
cells were thawed on ice followed by lysis with cold RIPA buffer (Thermo) using 
1 mL of RIPA per 107 cells.  Cell homogenates were sonicated at 50% intensity 
for 30 s on ice followed by incubation for 30 min on ice. Total cellular cholesterol 
and neutral lipids were extracted from cell lysates using the Folch method as 
previously described (100).  Briefly, total lipids were extracted from aliquots of 
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cell homogenates using chloroform: methanol (2:1) and partitioned using dH2O.
Organic phase solvents containing lipids were evaporated under nitrogen gas and 
resuspend in 0.5% (v/v) Triton X-100 solution in water. Total and free cholesterol 
were determined enzymatically using Amplex red cholesterol quantitation kit 
(Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacture’s 
protocol. Cellular cholesterol content was normalized to whole cell lysate protein 
concentrations. Protein was determined using the BCA assay (Thermo).  
Cell Culture Supernatant Protein Analysis  
 Protein expression of five pro-inflammatory mediators (IL-1β, IL-6, IL-8, 
TNF-α and IL-10) in AM cell culture supernatants collected at termination of ex-
vivo experiments were measured using a multiplex Procarta® Cytokine Profiling 
Kit (Affymetrix Santa Clara, CA) according to the manufacturer’s protocol. 
Profiling kits were processed on a Bio-Plex 200 multiplex bead-based array 
system and analyte concentrations determined using Bio-Plex Manager software 
suite version 6.0 (Bio-Rad, Hercules CA).  
Statistics 
 Statistical and power analysis of data was carried out with the GraphPad 
PRISM4 program and GraphPad Stat Mat 2 (GraphPad Software, Inc.). Contrasts 
of group means were computed using one or two factor ANOVA followed by 
Bonferroni post-hoc tests. Gene expression results will be expressed as means      
± SE of comparative fold differences. One and two factor repeat measures 
ANOVA will be used to analyze BAL cell gene and protein expression from 
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Ossabaw pigs. Diet, LPS and LXR were treated as independent variables. Mean 
differences of post-hoc analyses are considered significant when p value is < 0.05.  
RESULTS 
Body Weight and Lipid Profile after 28 Weeks of HF diet  
 At the end of 34 weeks of HF feeding mean body weights were 
significantly higher in pigs fed a HF and HFPB compared to pigs fed either a C or 
CPB diet (p < 0.01, Table 2).  Serum cholesterol levels in HF and HFPB fed pigs 
were significantly elevated compared to C and CPB fed animals (p < 0.001, Table 
2).  Daily gavage with L. casei had no effect on serum cholesterol levels in either 
C or HF fed pigs. There were no differences in plasma triglycerides among all the 
diet groups (Table 2).  
Cholesterol Analysis in Alveolar Macrophages  
 To determine whether an obesogenic, HF diet led to abnormal lipid 
accumulation in pulmonary macrophages, cellular CE and free cholesterol (FC) 
were analyzed in AM from pigs fed a HF obesogenic diet. Our data revealed th t 
AM from HF fed pigs had significantly higher concentrations of CE and FC 
compared to AM from C and CPB fed pigs (p < 0.001, Fig 1).  However, AM 
from pigs fed a HFPB diet did not have any increase in CE or FC compared to 
AM from C, CPB or HF fed pigs (Fig 1). There were no significant differences in 
CE and FC concentrations between AM from C and CPB fed pigs.  These data 
suggest that daily gavage with the probiotic L. casei can protect against AM lipid 
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accumulation due to a HF, obesogenic diet, even in the face of higher serum 
cholesterol levels.  
Gene Expression in Unstimulated AM cells 
 In order to determine whether an obesogenic, HF diet or supplementation 
with L. casei, was associated with changes to gene expression of the LXR axis, 
markers of foam cell development, and immune related genes (Table 1), RT-PCR 
analysis of unstimulated AM cells was undertaken. Figure 2A demonstrates th t 
animals fed a HF diet showed no significant changes to LXR or foam cell related 
marker gene expression compared to C fed pigs. However two genes related to 
cholesterol uptake, LDLR and esterification of free cholesterol, ACAT were 
significantly decreased in AM from CPB fed pigs compared to AM from C fed 
pigs (p < 0.05). Gene expression of CYP27A1, a gene involved in metabolism of 
cholesterol to the oxysterol 27, hydroxycholesterol, was increased 5-6 fold (Fig 2) 
in AM from HF and HFPB fed pigs, but this was not significant. Analysis of a 
panel of genes (Table 1) associated with onset of foam cell phenotype did not 
reveal any dietary effects on these markers in AM from any of the diet groups 
(Fig 2B). Analysis of gene expression of inflammatory mediators also fai ed to 
demonstrate any dietary effect either from HF or from L. casei supplementation 
(Fig 3). 
Elevated mRNA Levels of Pro-inflammatory Mediators in LPS-treated 




Augmented responsive of LPS mediated IL-1β mRNA levels in AM from HF fed 
pigs.  
 Others have reported that genetic ablation of ABCA1 leads to macrophage 
foam cell formation and an increased sensitivity to LPS.  We observed that AM 
isolated from HF and HFPB fed pigs had a 1.9 and 2.4 fold greater mRNA 
expression of IL-1β in response to LPS stimulation compared to AM from C fed 
pigs (Fig 4A) (p < 0.05). There was no evidence that the LPS mediated mRNA 
increase in IL-6, IL-10 or TNF-α was augmented in AM from HF fed pigs 
compared to AM from C fed pigs (Fig 4B-E).  The statistical difference between 
LPS mediated expression of IL-1β mRNA in AM from HF compared to C fed 
pigs does suggests an augmented response due to diet.  Two-way ANOVA, 
however, did not reveal a significant interaction between HF diet and LPS 
mediated IL-1β mRNA response. (p = 0.117).    
  We also observed that LPS stimulation resulted in significantly stronger 
mRNA response of IL-6, IL-8 in AM isolated from CPB fed pigs compared to C 
fed pigs, (p < 0.001 and p < 0.05 respectively (Fig 4B and C). This effect was 
most pronounced for LPS stimulation of IL-6 (Fig 4B). IL-10 mRNA levels also 
where elevated in AM from CPB fed pigs compared to C fed pigs (~9 fold vs. ~4 
fold), however this difference was not significant. There was a strong and 
significant interaction between CPB diet and LPS in IL-6 mRNA response (p = 
0.0003). Except for AM from HFPB fed pigs, LPS did not significantly increase 
mRNA levels of TNF-α in any of the diet groups.   
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Anti-inflammatory Effect of LXR activation. 
 Activation of LXR opposed the effects of LPS on mRNA expression of 
IL-1β in AM from HF and HFPB pigs (p < 0.001), but not in AM from C or CPB 
fed pigs (Fig 4A).  The hyper-responsive mRNA expression of IL-6 and IL-10 in 
AM from CPB fed pigs was significantly inhibited by LXR activation (p < 0.001, 
p < 0.05), respectively (Fig 4B and 4D). LXR activation significantly opposed 
LPS stimulation of IL-8 in AM from HF and CPB fed pigs (p < 0.01, p < 0.05), 
respectively, (Fig 4C).  
Protein Analysis of Cell Culture Supernatants 
 To examine whether AM from HF fed pigs also had heightened secretion 
of pro-inflammatory mediators, protein expression of cytokines IL-1β, TNF-α, IL-
6, IL-8 and IL-10 were analyzed in cell culture supernatants after 24 h of LPS and 
LXR stimulation from AM in each dietary group. The analysis revealed that 
protein expression of IL-1β was significantly increased by LPS stimulation in AM 
from all dietary groups (Fig 5A). IL-1β protein level from HF fed pigs was ~1.6 
fold higher than AM from C fed pigs, however this difference was not significat 
(Fig 5A, p = 0.021). There was no significant difference between LPS mediated 
increase in TNF-α protein between AM from C or HF fed pigs (Fig 5B). LPS 
mediated protein levels of TNF-α protein was ~2 fold lower in HFPB fed pigs 
compared to AM from HF fed pigs, this difference was marginally significant (p = 
0.09). No significant differences were observed for protein levels of IL-6, IL-8 or 
IL-10 from any treatments or diet groups (Fig 5C-E).  
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L casei supplementation opposed LPS mediated IL-1β protein levels 
 Protein levels of LPS mediated IL-1β protein expression in AM from 
HFPB was 2.5 fold lower than LPS mediated protein levels from AM HF fed pigs, 
(p < 0.05, Fig 5A black bars). LPS mediated TNF-α protein levels where  2.1 fold 
lower in AM from HFPB fed pigs compared to AM from HF fed pigs, however 
this effect was not significant (Fig 5B, p = 0.08). 
Anti-inflammatory Effect of LXR activation  
 The LXR ligand T09 significantly opposed LPS induced IL-1β protein 
expression in AM from HF fed pigs only (p < 0.05, Fig 5A). No significant anti-
inflammatory effect of LXR was observed for LPS mediated stimulation of TNF-
α, IL-6, IL-8 and IL-10 in AM from C, CPB, HF and HFPB fed pigs (Fig 5B-E).    
Effect of L casei Supplementation on LPS Antagonism of LXR and 
Cholesterol Metabolism Related Genes 
 Data from RT-PCR revealed that T09 mediated transcription of LXRα 
mRNA was opposed by LPS in AM from HF and HFPB fed pigs (Fig 6A, p < 
0.001 and p < 0.05 respectively).  LXR activation of ABCA1 mRNA was 
significantly inhibited by LPS in AM from C and HF fed pigs (p < 0.01 and p < 
0.05) respectively, but not in AM from CPB or HFPB fed pigs (Fig 6C). LPS also 
significantly inhibited LXR activation of ABCG1 mRNA in HF fed pigs (p < 
0.001, Fig 6D). This was not observed in AM from any other diet group (Fig 6D). 
LPS treatment had no effect on LXRβ mRNA levels either alone or in T09 treated 
AM from any of the diet groups (Fig 6B).   
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L. casei supplementation prevents LPS suppression of LXR mediated transcription 
of PPARγ and CH25H in AM from HF fed pig 
 25-hydroxycholesterol (25HC) is an LXR ligand synthesized from 
cholesterol by the microsomal enzyme CH25H (9, 56). We observed that LPS 
opposed LXR activation of CH25H mRNA in AM from C and HF fed pigs, but 
not in AM from CPB or HFPB fed pigs (p < 0.001 vs. ns, Fig 6E). LPS also 
significantly oppose LXR activation of PPARγ mRNA in AM from C and HF fed 
pigs (p < 0.05), this was not observed in AM from either CPB or HFPB fed pigs 
(Fig 6E).  
DISCUSSION  
 There is growing evidence that supplementation with some probiotic 
bacteria can positively modulate gut immunity and have a positive clinical effect
on treatment of inflammatory bowel diseases such as Crohn’s, infectious diarrhea, 
and Clostridium difficile infection (90-93). The beneficial effects of probiotic are 
strain specific as some have been shown to positively influence inflammation 
(135). Until recently it was believed that the mechanisms of action of probiotic 
bacteria were limited to the gastrointestinal tract, but recent findings su gest that 
probiotics may lead to systemic benefits on host immunity and inflammatory 
conditions outside of the gut (90-93). In the present study we report that dietary 
supplementation with the probiotic bacteria L. casei is significantly associated 
with decreased CE accumulation in AM. We also report that dietary 
supplementation with L. casei opposed LPS mediated gene suppression of 
ABCA1, an LXR responsive genes vital to maintaining cholesterol homeostasis in 
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pulmonary AM and pneumocytes (30). L. casei also significantly decrease the 
protein expression of LPS mediated IL-1β protein levels. Collectively, these data 
demonstrate a role for L. casei in modulating AM cholesterol metabolism, LXR 
responsive genes and pro-inflammatory cytokine expression. This suggests that 
supplementation with L. casei may benefit pulmonary abnormalities where both 
hypercholesterolemia and chronic inflammation are involved. 
HF feeding was associated with Cholesteryl-ester Accumulation in AM  
 The hallmark of foam cell formation is accumulation of CE in 
macrophages (137). Analysis of cholesterol extractions from AM from BAL fluid
lysates revealed that AM from pigs fed a HF diet had significantly higher 
concentrations of CE compared to AM from control diet fed animals (Fig 1). This 
strongly suggests an increase in the presence of foam cell AM in bronchoalveolar 
passages of HF fed pigs for three reasons: i. It is well documented that the 
majority of cells isolated from BAL lavage are AM, ii. Contamination from either 
epithelial cells, or other immune cells in the lavage would have little contribution 
to the cholesterol analysis because these cell types typically do not accumulate 
CE, and iii: The majority of cholesterol found in type 2 pneumocytes is 
unesterified and associated with lamellar body surfactant proteins (138-141).  
 The presence of foamy AM in BAL fluid of HF fed animals is consistent 
with the significant increase in serum levels of cholesterol observed in these 
animals (Table 1) and consistent with data demonstrating that dietary lipids can 
positively increase lipids levels in the alveolar compartment (138-141).  
Moreover, the CE concentration in AM from HF fed animals (~10 µg/mg protein) 
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is consistent with the CE concentrations observed in foam cell macrophages 
isolated from high fat fed mice (18). Future studies will be conducted to 
determine if the AM cholesterol profile is also mirrored in the AM within the lung
parenchyma.  
 However an unanswered question is whether the source of excess 
cholesterol in AM was derived directly from the diet (i.e. LDL or scavenger 
receptors) or from a source of pulmonary cholesterol associated with surfactant 
protein (SAP). SAP is synthesized by pulmonary type 2 pneumocytes (type 2 
cells), and is composed of 90% lipids, the majority of which is phospholipids and 
10-15% neutral lipids, almost all of which are in the form of FC (138). Pulmonary 
surface SAP can be recycled and reused by type 2 cells or catabolized by AM. 
Internalization of adsorbed surfactant proteins and lipids is a vital function of AM 
and the cycle of maintaining pulmonary surface tension (138). Although both type 
2 cells and AM can internalize SAP and lipids, ex vivo studies have demonstrated 
that AM typically internalize three to four times more surfactant protein and lipid 
than type 2 cells (138-141). SAP bound cholesterol represents approximately 80% 
of the cholesterol found in the lungs and the majority of this cholesterol is derived 
from circulating lipoprotein particles (138-141). Type 2 cells express LDL and 
VLDL receptor in their basolateral membrane where they can rapidly incorporate 
serum cholesterol and triglyceride from circulating lipoprotein particles (138-
141). Therefore the largest pool of cholesterol that AM in the alveolar space 
would be exposed to is potentially from internalization of lipids associated with 
lamellar body surfactant proteins. Studies of rat lung perfusions with radio labeled 
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lipoproteins demonstrated that surfactant cholesterol concentrations are increased 
by exogenous cholesterol incubations and type 2 cells preferentially incorporate 
cholesterol from serum lipoproteins, with less than 1% being derived from de 
novo cholesterol synthesis (138-141). Animal models have also demonstrated that 
obesogenic diet and hyperlipidemia can increase lipid uptake by type 2 cells and 
increased the deposition of SAP lipids on the surface of alveoli (138-141). 
Collectively, these data suggest that the source of the increased CE in AM from 
HF fed animals could be derived from type 2 cell surfactant lipids. This may have 
overarching consequences not only to normal lung physiology, but to the innate 
immune response of AM as it has been demonstrated that increased surfactant 
lipids can negatively impact AM innate immunity and that foam cell macrophages 
are, immuno-compromised, highly unstable, atherogenic and prone to apoptosis 
(18).  
 Gene expression profiling of AM from BAL fluid did not reveal any 
significant differences in relative mRNA levels of scavenger receptors such as 
CD36, CD209, MSR-1 and SCARB2 in AM of HF fed pigs (Fig 2B), but there was 
a significant decrease in LDLR and ACAT mRNA in AM from CPB fed pigs 
compared to C fed pigs (Fig 2A). The decreased expression of LDLR and ACAT 
mRNA was not reflected in the cholesterol profile of these cells (Fig 1), and also 
does not correlate with what would be expected in cells with lower cellular 
cholesterol levels, because decreased levels of cholesterol in the endoplasmic 
reticulum (ER) leads to an increase in LDLR receptor expression (9). ACAT
mRNA levels might not necessary be reflected in the cholesterol profile of th se 
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cells as it has been demonstrated in other cell types (142). However, if 
mechanistically L. casei supplementation resulted in a net decrease in cholesterol 
uptake by AM, this may not have been reflected in the gene expression changes in 
AM from HFPB fed pigs because of the dynamics nature of cholesterol 
metabolism under a HF diet. It would also be important to examine the effects of 
L. casei supplementation on hepatic expression of cytochrome P-450 cholesterol 
7-alpha-hydroxylase (CYP7A1). CYP7A1 is responsible for the rate limiting 
conversion of hepatic cholesterol to bile acids and is also under the transcriptional 
regulation of LXRα (9).  There is experimental evidence demonstrating that the 
probiotic bacteria Lactobacillus plantarum can modulate cholesterol levels by 
increasing hepatic conversion of cholesterol to bile salts through upregulation of 
CYP7A1 (146).  
 Two studies have demonstrated that mice lacking expression of either 
ABCA1 or ABCG1, present with gross pulmonary lipidosis and the presence of 
lipid-laden foamy AM (51-54). This demonstrates a role for LXR and the 
ABCA1/G1 efflux pathway for maintain normal lung cholesterol homeostasis.  
Gene expression analysis did not reveal any significant differences in LXRα,
LXRβ, ABCA1 and ABCG1 mRNA expression between AM from HF fed pigs and 
C fed pigs demonstrating that the observed accumulation of CE in AM is not 
reflected by mRNA changes to expression of LXR or ABCA1/G1 transporters. 
This does not rule out the involvement of the LXR-ABCA1 pathway in 
development of a lipid laden AM phenotype because mRNA and protein levels of 
ABCA1 and LXR expression in human atheromas do always not correlate (146).  
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L. casei Supplementation Prevents Cholesteryl-ester Accumulation in AM 
from HF fed pigs. 
 Analysis of lipid extracts from BAL fluid in HF fed pigs supplemented 
with L.casei revealed a significantly lower concentration of CE compared to AM 
from HF fed pig. There was no effect of L casei alone on cholesterol 
accumulation in AM from control fed pigs, which may suggest that any hypo-
cholesterolemic effect of this strain of L. casei occurs only in the context of gross 
lipid burden.  It is also important to note that the serum cholesterol profile of 
HFPB fed pigs significantly elevated (~100 ng/dl higher) than HF fed pigs (Table 
1, p < 0.05), and despite this difference, the AM of HFPB clearly showed less 
evidence of CE accumulation (Fig 1).  This suggests that the cholesterol lowering 
effect of this strain of L. casei may be cell specific and is not reflected by the 
serum cholesterol profile. Two primary mechanisms for the lipid lowering effect 
of probiotics have been proposed. The first involves probiotic assimilation of 
intestinal lipids, thus decreasing the availability pool of post prandial cholesterol 
lipids for absorption (90). The second involves an increase in probiotic bile salt 
hydrolase (BSH) activity (90-93).  Bacterial BSH catalyzed the deconjugation of 
the two major bile salts; cholic and chenodeoxycholic acid, which decreases their 
reabsorption across the entire length of small intestine and increases their removal 
in feces (93). It is estimated that approximately 5% of all bile acids and free 
cholesterol secreted in the small intestine are removed in the feces by this 
mechanism, which has been shown to have modest effects on serum cholesterol 
levels (93). However these mechanisms do not appear to be involved in the 
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cholesterol lowering effect observed in this study because L. casei 
supplementation had no effect on serum lipids in either PB or HFPB fed pigs.  
The findings in the current study may reflect a unique lipid modulating property 
of this strain of L. casei and sugges t that studies reporting strain specific effects 
on serum cholesterol in human and animals may overlook tissue or cell specific 
lipid modulating properties.  
Increased LPS mediated IL-1β mRNA Expression in AM from HF Fed Pigs 
 Gene expression and protein analysis revealed that a HF diet was 
associated with a significantly higher mRNA expression of IL-1β in response to 
LPS in AM from HF fed pigs compared to C fed pigs; however this effect did not 
carry over to the protein levels (Fig 4A and 5A).  AM from HF had approximately 
a 2 fold increase in LPS mediated IL-1β mRNA levels compared to AM from C 
fed pigs (Fig 4A). This is consistent with the increased levels observed in studies 
of lipid laden-AM from ABCG1 -/- null mice which display an augmented 
response to LPS (53). Still, in this study we did not observe the broad 
augmentation of LPS mediated induction of inflammatory mediators as reported 
in studies of lipid laden LPS or bacterial challenged macrophages (53-55). A post-
hoc power analysis suggests that the current study design with a 4 diet groups and 
a sample of 5 animals, is approximately 30% underpowered to detect small 
differences between LPS mediated responsive gene expression across four diet 
groups and might explain the absence of a strong interaction between a HF diet 
and AM inflammatory response in the current study. This information is 
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important in for design of future studies designed to examine the same questions 
in the current pig model. 
 Despite the limitations of the current study design on these parameters, the 
significant increase in IL-1β mRNA levels in HF fed pigs suggests that animals on 
this diet would experience an augmented pulmonary immune response if 
challenged with an airborne pathogen.  It is tempting to hypothesize that this 
would enhance host pulmonary immunity as it has been demonstrated in mice 
models of pulmonary lipidosis; however these studies also demonstrated that 
increased presence of AM foam cells is positively associated with increased 
pulmonary defects and host mortality. Future studies should be undertaken to 
determine whether HF feeding adversely affects pigs challenged with air borne 
pathogens.  However deeper examination of the interactions between diet, 
pulmonary lipid accumulation and pulmonary inflammatory response, would 
require a larger cohort of animals in order to detect any small but significant 
differences which may occur due to these experimental parameters.  
Effects of L. casei Supplementation on Expression of Inflammatory 
Mediators 
 Post-hoc analysis revealed that LPS mediated IL-1β protein expression in 
AM from HFPB fed pigs was significantly lower than that in AM from HF fed 
pigs (p < 0.05, Fig 5A). LPS mediated TNF-α protein expression was also 
decreased two fold in HFPB compared to HF fed pigs, but this effect was nearly 
significant at p < 0.08, Fig 5B).  Protein expression of other cytokines did not 
reveal further evidence that L. casei had any anti-inflammatory effect in AM. 
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However, taken together the decreased IL-1β and TNF-α protein levels do suggest 
that L. casei discharged an anti-inflammatory effect in AM from HFPB fed pigs. 
Both IL-1β and TNF-α are integral mediators of the innate immunity and 
remediation of pathogenic infection (51-54). However some conditions such as 
obesity, pulmonary cystic fibrosis or chronic obstructive pulmonary disorder 
(COPD) are associated with elevated levels of systemic and pulmonary cytokine 
levels and this is believed to have adverse effects on host immunity and normal 
tissue function (51-54).  The observed anti-inflammatory effect of L. casei adds to 
a growing body of data demonstrating that probiotic bacteria can modulate 
systemic ant-inflammatory mediators outside of gut mediated mucosal immunity 
(90-93).  L. casei may prove to be beneficial in ameliorating inflammation in 
pathologies where chronic inflammation has been observed. A fundamental 
question is whether the dampened immune response in AM from HFPB fed pigs 
would translate to an impaired immune response.  
 AM from PB fed pigs showed augmented mRNA expression of IL-6, IL-8 
and IL-10, however, these mRNA changes where not reflected in supernatant 
protein levels.  Future studies examining this effect should examine earlier time 
points as other have demonstrated that L. casei inoculated mice have augmented 
release of IL-6 and TNF-α up to 8 h post-infection compared to control mice but 





L. casei Supplementation Prevents LPS Antagonism of ABCA1 and ABCG1 
Expression 
 It is recognized that cholesterol plays an integral role in the pathogenesis 
of atherosclerosis and replication of human immunodeficiency virus -1 (HIV-1) in 
host cells (45, 46). Foam cells are highly apoptotic and undergo necrosis and 
calcification leading to release of their cholesterol and cytokine rich vauoles 
(18). This cascade is central to the pathogenesis of atheroma formation, but may 
also negative impact host immunity as foam cell macrophage may be immuno-
compromised (126, 127). Both viral and bacterial pathogenic products lead to 
impaired cholesterol metabolism in macrophages and lead to foam cell formation 
suggesting a potential mechanism for bacterial suppression of innate immunity 
(126).  
 In the current study we observed that the TLR4 ligand LPS opposed LXR 
transcription of ABCA1, ABCG1 in AM. This is consistent with a study by 
Tontonoz et. al. that demonstrated TLR3 and TLR4 activation strongly oppose 
transcriptional activation of LXR responsive genes ABCA1 and ABCG1 in 
macrophages through a mechanism involving IRF3 trans-repression of LXR 
transcriptional activation (130). Others have demonstrated associations between 
viral and bacterial products and foam cell formation in macrophages, but the 
study by Tontonoz et. al. was the first to characterize specific cross talk be ween 
TRL4 and LXR in antagonism of macrophage cholesterol metabolism and 
cholesterol efflux (130).  Other studies have subsequently shown that both IRF3 
and MyD88 are involved in antagonism of LXR signaling (129, 130). Our data is 
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the first to demonstrate that LPS/TLR4 can oppose LXR transcription in AM, but 
it is unclear what affect this may have on AM cholesterol metabolism.  Loss of 
ABCA1 negatively impacts cholesterol efflux and can lead to macrophage foam 
cell transformation when accompanied by increased serum cholesterol levels. 
Therefore, this data suggests that if exposed to chronic TLR4 challenge, that pigs 
fed a HF fed diet may be at increased risk for AM foam cell development.  
Further experiments should be conducted to examine the effect that LPS 
antagonism may have on AM cholesterol metabolism and any potential 
involvement of LXR-ABCA1 in vivo.  
 Gene expression analysis also revealed that AM from both CPB and 
HFPB fed pigs were resistant to LPS antagonism of LXR mediated transcription 
of ABCA1 mRNA revealing a potential novel mechanism behind the cholesterol 
lowering effect of L. casei.  This finding was interesting because TLR4 
antagonism of LXR responsive genes in peritoneal macrophages is unopposed by 
LXR ligand activation. Our data is the first to demonstrate probiotic opposition of 
TLR4 mediated suppression of the LXR axis. This effect by L.casei might 
specifically involve antagonism of MyD88 or IRF3 suppression of LXR since it 
has been demonstrated that both pathways can oppose LXR and MyD88 is 
involved in some of the immune-modulating properties of some lactobacillus 
bacteria (131). The diminished LPS mediated cytokine secretion of IL-1β and 
TNF-α in AM from L casei supplemented animals (Fig 6), does suggest an 
interaction between L. casei and TLR4 signaling and therefore provides the 
rationale to examine interactions between L. casei on some of the downstream 
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effectors of TLR4. However gene expression in unstimulated AM did not 
demonstrate any antagonism of the TLR4 mediated expression of inflammatory 
mediators by L. casei, therefore a MyD88 independent pathway involving IRF3 
might be equally involved. The apparent lack of LPS antagonism of LXR 
mediated transcription of ABCA1 and ABCG1 in AM from PB and HFPB fed 
supports a specific involvement of L. casei in antagonizing LPS suppression of 
the LXR axis.   
 Expression of PPARγ, and CH25H, two genes involved in cholesterol 
metabolism, was antagonized by LPS in T09 stimulated AM, however this was 
not observed in AM from PB and HFPB fed pigs. PPARγ, can indirectly promote 
cholesterol efflux in macrophages through increased regulation of LXRα, whereas 
CH25H is a key enzyme in metabolism of cholesterol to the LXR ligand 25HC 
(18). This data supports a broader mechanism through which L. casei can exert its 
modulation of lipid and cholesterol axis in AM.   
 It is feasible that hypothesize that L. casei antagonism of LPS/TLR4 
suppression of the LXR axis is a mechanism supporting the decreased 
accumulation of CE in HFPB fed pigs. However future studies should examine 
whether LXR mediated cholesterol efflux is antagonized by LPS treatment and 
whether L. casei supplementation can abrogate that. Nevertheless, the data in the 
current study collectively these data demonstrate a cell specific lipid lowering 
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Figure 1. AM Cholesterol Profile. Total lipids were extracted from 1 x 108 AM 
isolated from Ossabaw pigs fed either a control diet (C), control + probiotic 
(CPB), high fat (HF) or high fat + probiotic(HFPB) and used to determine total 
cellular cholesterol-esters and free cholesterol. Cholesteryl-esters were calculated 
by subtracting the concentration of free cholesterol (µg/mg cellular protein) from 
total cholesterol concentration (µg/mg cellular protein).  Data are representative of 
the mean ± SE of (n=5) animals per dietary group. Error bars with an asterisk (*) 
indicate significant difference between HF and C where * =p < 0.05. Error bars 
with a number sign (#) indicate a significant difference between HFPB and HF 










Figure 2. Gene Expression of LXR and Lipid Metabolism Gene in 
unstimulated AM from C, CPB, HF and HFPB fed pigs. Total RNA was 
extracted from freshly isolated BAL cells, reversed transcribed to cDNA and 
analyzed for genes expression using RTPCR as described above. Grouped genes 
surround by yellow box are related to LXR and cholesterol metabolism. Grouped 
genes surrounded by a blue box are markers of foam cells development. Gene 
expression is reported as means ± SE of fold change relative to C fed animals. 
Error bars with an asterisk (*) indicate a significant difference between C and 








Figure 3. Gene Expression of Inflammatory Mediators in unstimulated AM 
from C, CPB, HF and HFPB fed pigs. Total RNA was extracted from freshly 
isolated AM, reversed transcribed to cDNA and analyzed for gene expression 
using RTPCR as described in Materials and Methods. Gene expression is reported 
as means ± SE of fold change relative to C fed animals. A, mRNA expression of 
IL-β in unstimulated AM. B, mRNA expression of TNF-α- in unstimulated AM. 
C, mRNA expression of IL-6 in unstimulated AM. D, mRNA expression of COX-
2 in unstimulated AM. E, mRNA expression of IL-8 in unstimulated AM. F, 








Figure 4. Gene Expression of Inflammatory Mediators in AM treated with 
LPS and a LXR ligand from C, CPB, HF and HFPB fed pigs. AM were 
seeded at a density of 2.5 x 106 cells/mL and treated with either: vehicle (0.125% 
DMSO), 0.5 ng/mL LPS, 2.5 µM of the synthetic LXR ligand T09 or LPS + T09 
for 24 h. Gene expression is reported as means ± SE of fold change relative to 
vehicle treated control. Error bars with p values are contrasts between LPS and 
vehicle treated AM. Errors bars with an asterisk (*) represents a significant 
difference between LPS from either: HF, HFPB or CPB and LPS from C fed pigs 
with p < 0.05. Error bars with a number sign (#) indicate a significant difference 
between LPS and T09 + LPS treated AM with # p < 0.05, ## p < 0.01, and ### p
< 0.001 or not significant, ns. A, mRNA expression of IL-β in AM. B, mRNA 
expression of IL-6 in AM. C, mRNA expression of IL-8 in AM. D, mRNA 





Figure 5. Cell Culture Supernatant Protein Expression of Inflammatory 
Mediators in AM from C, CPB, HF and HFPB fed pigs.  AM were seeded at a 
density of 2.5 x 106 cells/mL and treated with either: vehicle (0.125% DMSO), 
0.5 ng/mL LPS, 2.5 µM of the synthetic LXR ligand T09 or LPS + T09 for 24 h. 
Cell culture supernatant were collected and analyzed for protein expression on a 
Bio-Rad Protein Bio-plex system. Protein is expressed as pg/mL and reported as 
means ± SE.  Error bars with p values are contrasts between LPS and vehicle 
treated AM.  Errors bars with an asterisk (*) represents a significant difference 
between LPS from HFPB and LPS from HF fed pigs with p < 0.05. Error bars 
with a number sign (#) indicate a significant difference between LPS and T09 +
LPS treated AM with # = p < 0.05.  A, Supernatant protein expression of IL-β in 
AM from. B, Supernatant protein expression of TNF-α  in AM. C, Supernatant 
protein expression of IL-8 in AM. D, Supernatant protein expression of IL-6 in 






Figure 6. L. casei prevents LPS antagonism of LXR and Lipid Related Gene 
Expression. AM from C, CPB, HF and HFPB fed pigs were seeded at a density 
of 2.5 x 106 cells/mL and treated with either: vehicle (0.125% DMSO), 0.5 µg/mL 
LPS, 2.5µM of the synthetic LXR ligand T09, or LPS + T09 for 24 h. Gene 
expression is reported as means ± SE of fold change relative to vehicle treated
control. Error bars with p values indicate significant differences between T09 and 
T09 + LPS. A, LPS modulation of LXRα mRNA in T09 stimulated AM. B, LPS 
modulation of LXRβ mRNA in T09 stimulated AM. C, LPS modulation of 
ABCA1 mRNA in T09 stimulated AM. D, LPS modulation of ABCG1 mRNA in 
T09 stimulated AM. E, LPS modulation of PPARγ  mRNA in T09 stimulated 
AM. F, LPS modulation of CH25H  mRNA in T09 stimulated AM.
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Chapter 5:  Perspectives  
Studies of LXRs as Modulators of Lipid Raft Domains in PCa Cells 
 The current study clearly demonstrated that under conditions of LXR-
ABCA1 mediated cholesterol efflux, that lipid raft domains are negatively 
affected in PC-3 cells. There are still a number of questions that need to be 
examined if LXR ligands are to be categorized as modulators of lipid raft 
signaling in PCa. The first and the most important is disruption of raft domain 
patching under LXR-ABCA1 or ABCG1 mediated cholesterol efflux results in a 
decrease in raft associated receptor signal transduction. More specifically, 
whether there is a decrease in the presence of receptors such as CXCR4 and IL-
6R in raft domains during ligand activation and whether this is associated with 
attenuation of downstream signaling. Freeman et al. demonstrated that modulation 
of de novo cholesterol synthesis by statins specially reduced assembly of IL-6R 
into raft domains and AKT mediated signaling in LNCaP cells (97).  Pommier AJ 
et al. took this further and demonstrated that mice injected with LNCaP cell 
xenografts and treated with the LXR ligand T09 showed a significant reduction in 
raft domain integrity and AKT mediated survival. Unlike previous studies of the 
anti-PCa effect of LXR ligands, the current study demonstrates for the fi st time 
that raft domains in PC-3 cells are specifically impacted by cholesterol efflux 
conditions involved apo A-I.   
 An inverse association between serum HDL cholesterol and risk for 
prostate and other cancers has been reported (64).  These data would suggest 
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therapies aimed at increasing either circulating apo A-I or LXR mediat  RCT 
would also be protective because ABCA1 mediated cholesterol efflux is rate 
limiting in HDL genesis. The current project potentially ascribes a mechanism to 
the anti-PCa effect of increased HDL cholesterol, since raft domains where only 
negatively impacted when both apo A-I and T09 where present. Future studies 
examining the specific effects of LXR mediated cholesterol efflux on raft domain 
dependant signal transduction are warranted. Moreover, animal studies examining 
the effects of LXR mediated HDL biosynthesis on PCa progression would also 
increase understanding of the potential impacts that LXRs can have in not only 
protectively against atherosclerosis but also PCa and other cancers inversely 
affected by serum HDL levels. 
Studies of Isoflavones as Modulators of the LXR axis in PCa Cells 
 Despite the significant increase in ABCA1 and ABCG1 mRNA levels in 
both PCa cells line, a significant increase in cholesterol efflux was not observed. 
One reason this might have occurred is because that protein levels of ABCA1 and 
ABCG1 were not significantly increased by isoflavones. This would need to be 
confirmed in future studies examining the effects of these compounds on the LXR 
axis. Secondly, ABCA1 stability is positively regulated by phosphorylation by a 
PKA during cholesterol efflux (118). The current study did not examine whether 
ABCA1 protein stability is varied compared to those observed when induced by 
endogenous or synthetic LXR ligands.  Nevertheless if ABCA1 or ABCG1 
protein levels are significantly increased by isoflavones, further studies examining 
other biological effects of these transporters in PCa cells are warranted. This 
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comes at a time when there is interest in developing novel ligands where are 
capable of activation LXR responsive genes specifically through LXRβ to prevent 
LXRα driven hepatic lipidosis.  The current study did demonstrate a role for only 
LXRβ in isoflavone regulation of ABCA1 and ABCG1. Future studies examining 
specific interactions between isoflavones and the ligand binding domain of LXRβ
could also determine whether there is a direct interaction between isoflavones and 
LXRβ or whether the observed effects are indirect.  
Studies of HF diet and Probiotics on LXR and Inflammatory Mediators in 
AM 
 The current study examined a number of important questions involving 
both HF diets and dietary supplementation with probiotic bacteria.  One important 
observation was the increased accumulation of CE in AM from HF fed pigs. This 
may have implications to human health for a number of reasons.  If left 
unresolved, AM foam cells (defined by accumulation of CE) clearly have an 
altered immune response. This has been demonstrated in studies of animals with 
genetically impaired LXR mediated cholesterol efflux and shows that AM foam
cells are hyper-responsive to the presence of pathogens. Although in the short 
term these animals appear to have better clearance of intra-tracheal derived
bacteria, long term survival of animals with AM foam cells is significantly 
decreased post-infection. This is intuitive and may provide new insight to the 
deleterious effects of obesogenic diets and hyper-cholesterolemia on human 
health. The strength of the current project lies within the use of wild type animals 
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to demonstrate this effect of HF feeding on AM cholesterol profile, while other
studies have used genetically altered mice to achieve similar effects.  
 Another important finding in this study was the apparent lack of 
antagonism of LPS on LXR mediated transcription of ABCA1 and ABCG1 in 
AM from CPB and HFPB fed pigs. This observation is relevant to human health 
because of the body of data demonstrating that bacteria and viral antagonism of 
LXR mediated transcription impairs macrophage cholesterol efflux and increases 
formation of foam cell an immunocompromised phenotype.  The observations 
from this study demonstrate that L. casei feeding abrogated LPS mediated 
suppression of the LXR axis. This would be a novel finding as other studies have 
failed to demonstrate that synthetic LXR ligands can oppose LPS mediated 
suppression of ABCA1 and ABCG1. Moreover, these observations may also 
provide a mechanism for the lack of CE accumulation in AM from HFPB fed 
pigs. The current data suggests an enhanced effect of LXR ligand against the 
response of LPS. Future studies specifically examining whether L. casei feeding 
can inhibit LPS mediated opposition to LXR mediated cholesterol efflux should 
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